Health
Excel
Ear Disorders Dataset – Hearing & Ear Conditions Database
Ear Disorders Dataset
The Ear Disorders Dataset is a structured medical database containing a comprehensive list of conditions affecting the ear and hearing system.
Ear disorders can impact hearing, balance, and overall quality of life, ranging from common infections to chronic and complex conditions. This dataset provides organised information to support medical research, healthcare analytics, and application development.
Each record includes key clinical details such as condition descriptions, affected ear structures, common symptoms, severity levels, and treatment approaches.
The dataset has been cleaned and structured for easy integration into spreadsheets, databases, and analytical tools.
It is ideal for healthcare developers, researchers, educators, and data scientists working with hearing and ear health data.
Dataset Contents
The dataset includes fields such as:
- Condition Name
- Description
- Affected Area (Outer Ear, Middle Ear, Inner Ear)
- Common Symptoms
- Severity Level
- Disease Category
- Risk Factors
- Treatment / Management
Example Conditions Included
- Otitis Media
- Tinnitus
- Hearing Loss
- Meniere’s Disease
- Earwax Impaction
- Labyrinthitis
- Otosclerosis
- Acoustic Neuroma
- Eustachian Tube Dysfunction
- Perforated Eardrum
...and many more ear and hearing-related conditions.
Data Preview
12 columns
25 rows shown
| No. | Disease Name | Category | Primary Cause / Etiology | Prevalence | Age of Onset | Key Symptoms | Affected Organ(s) | Diagnostic Method | Treatment Approach | Prognosis | ICD-10 Code | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ▸ External Ear Disorders | |||||||||||
| 2 | 1 | Auricular Keloid | External Ear Disorders | Auricular keloids are benign fibroproliferative growths characterized by excessive deposition of extracellular matrix components (primarily type I and type III collagen) extending beyond the boundaries of the original wound or inflammatory site on the auricle. The pathogenesis involves dysregulation of the wound healing process, specifically an imbalance between collagen synthesis and degradation, with upregulation of transforming growth factor-beta (TGF-beta), platelet-derived growth factor (PDGF), and insulin-like growth factor-1 (IGF-1) signaling in keloid fibroblasts. Keloid fibroblasts demonstrate increased proliferative capacity, resistance to apoptosis (via upregulation of Bcl-2 and downregulation of p53), and excessive collagen production (up to 20 times normal fibroblast output). The most common precipitating factor for auricular keloids is ear piercing, accounting for 50-75% of cases, followed by otoplasty, burns, trauma, and spontaneous formation (rare). Ear piercing through the lobule is the most common site, but cartilage piercings (helix, tragus) can also trigger keloid formation. A strong genetic predisposition exists, with keloid-prone individuals often having a family history in first-degree relatives; genome-wide association studies have identified susceptibility loci on chromosomes 1q41, 3q22, and 15p21. The auricle is one of the most common sites for keloid formation due to the constant tension on ear piercings from jewelry and the relative immobility of auricular skin. | Keloids overall affect approximately 4.5-16% of the general population, with significantly higher rates in individuals of African descent (6-16%), Hispanic ethnicity (5-10%), and Asian descent (4-8%) compared to Caucasian populations (0.5-2%). Auricular keloids specifically represent approximately 25-30% of all keloid cases. Among individuals with ear piercings, keloid formation occurs in approximately 2.5-5% overall, but in 15-30% of keloid-prone individuals (those with a personal or family history of keloids). The condition is equally common in males and females when adjusted for piercing rates. Peak incidence occurs during the second and third decades of life, correlating with peak piercing rates and hormonal factors (puberty, pregnancy) that may promote keloid growth. | Most commonly develops between ages 10 and 30 years, with peak onset during adolescence and early adulthood, corresponding to peak ear piercing activity. Keloids are rare before puberty and after age 65, suggesting a hormonal influence on keloid biology. During pregnancy, existing keloids may enlarge due to elevated estrogen and progesterone levels, and new keloids may form more readily. There is no absolute age limit, and keloid formation has been reported from infancy to old age. The time from the inciting event (piercing, surgery, trauma) to keloid development ranges from weeks to years, with most forming within 3-12 months. | A progressively enlarging, firm, smooth, rubbery mass at the site of prior ear piercing, trauma, or surgery is the typical presentation. The keloid extends beyond the original wound margins, distinguishing it from a hypertrophic scar. Pruritus is reported in 50-70% of patients and can be the most distressing symptom. Pain or tenderness, particularly with pressure from telephones, headsets, or sleeping on the affected side, is common. The keloid surface is typically shiny, taut, and may be hyperpigmented (darker than surrounding skin) or erythematous. Auricular keloids can achieve significant size, with some earlobe keloids growing to several centimeters in diameter, causing cosmetic disfigurement and functional problems. A dumbbell or mushroom configuration may develop when a keloid grows on both sides of an earlobe piercing, connected through the piercing tract. | Auricle (pinna): earlobe most commonly, followed by helix, antihelix, tragus; skin and subcutaneous tissue | Clinical diagnosis based on characteristic appearance of a firm, raised, well-circumscribed mass extending beyond the original wound margins at a typical auricular location. Differentiation from hypertrophic scar (confined to wound margins, often regresses spontaneously over 12-18 months) is essential for treatment planning. Excisional biopsy with histopathologic examination may be performed for atypical lesions, revealing thick, randomly oriented hyalinized collagen bundles with a paucity of elastin fibers, increased mucin deposition, and a relatively acellular central zone. Ultrasound can characterize the depth and vascularity of the lesion and aid in treatment planning. Dermoscopy may reveal characteristic features including a shiny white background with red areas representing blood vessels. Photography with standardized views is important for documenting baseline size and monitoring treatment response. In rare cases, dermatofibrosarcoma protuberans or other soft tissue tumors must be excluded, particularly for rapidly growing or recurrent lesions. | Multimodal therapy combining surgical excision with adjunctive treatment yields the best outcomes, as excision alone has a recurrence rate of 45-100%. The current gold-standard approach is surgical excision followed by immediate postoperative intralesional corticosteroid injection: triamcinolone acetonide 10-40 mg/mL injected into the wound margins at the time of closure, repeated every 3-4 weeks for 3-6 sessions. Pressure therapy using custom-fitted pressure earrings (Zimmer clip or similar devices) applied for 8-24 hours daily for 6-12 months provides continuous mechanical compression. Silicone gel sheeting applied for 12-24 hours daily for 3-6 months flattens and softens the scar. Intralesional 5-fluorouracil (5-FU) 50 mg/mL alone or combined with triamcinolone (in a ratio of 9:1 or 3:1) injected at 0.1 mL per cm of scar every 1-2 weeks for 8-12 sessions has shown recurrence rates of 19-28%. Adjuvant radiation therapy (electron beam or superficial X-ray) delivering 12-20 Gy in 3-4 fractions beginning within 24-48 hours of excision reduces recurrence to 10-20%. Cryotherapy with liquid nitrogen applied for two 10-30 second freeze-thaw cycles every 3-4 weeks can reduce keloid volume but carries a risk of hypopigmentation. Laser therapy (585 nm pulsed dye laser or 1064 nm Nd:YAG) can reduce erythema, volume, and symptoms. | Recurrence is the primary challenge in auricular keloid management. Excision alone without adjunctive therapy has an unacceptably high recurrence rate of 45-100%. Combined excision with intralesional corticosteroids reduces recurrence to 25-50%. The most effective multimodal approaches (excision plus radiation, or excision plus 5-FU plus corticosteroids plus pressure therapy) achieve recurrence rates of 10-25%. Patient satisfaction with combined therapy is reported at 70-85%. Keloids do not undergo malignant transformation. Psychological impact can be significant, particularly in visible locations like the ear, and cosmetic concerns are a major driver of treatment-seeking behavior. Patients with a strong family history of keloids and those with multiple previous recurrences have the highest risk of treatment failure. Prevention in keloid-prone individuals includes avoidance of elective ear piercings and immediate prophylactic treatment of any unavoidable auricular wounds. | L91.0 |
| 3 | 2 | Bullous Myringitis | External Ear Disorders | Bullous myringitis is an inflammatory condition characterized by the formation of hemorrhagic or serous bullae (fluid-filled blisters) on the tympanic membrane and adjacent deep external auditory canal skin. The condition was historically attributed to viral etiologies (influenza, paramyxovirus), but contemporary evidence suggests that bacterial pathogens are the primary cause in most cases, with Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolated from bullae aspirates in 50-70% of cases, the same organisms responsible for acute otitis media. Mycoplasma pneumoniae was previously considered a major cause but is now thought to account for fewer than 10% of cases. The pathogenesis involves infection of the tympanic membrane epithelium (the outer keratinized squamous layer), with the inflammatory response causing subepithelial fluid accumulation that separates the epithelial layer from the fibrous middle layer, forming bullae. The condition frequently coexists with acute otitis media (concurrent middle ear effusion in 50-70% of cases), supporting the theory that it represents a variant of acute otitis media with particular tympanic membrane involvement rather than a completely separate entity. Seasonal distribution parallels that of upper respiratory infections and acute otitis media, with peak incidence in winter months. Some cases are associated with concurrent upper respiratory tract infections or influenza-like illness. | Relatively uncommon as an isolated diagnosis, with an estimated incidence of 1-2% of all acute ear infections. Historically, bullous myringitis was considered more common, but improved diagnostic criteria have narrowed the definition. The condition represents approximately 5-10% of acute otitis media presentations when specifically sought on otoscopy. True incidence is likely underestimated because mild cases with small bullae may be missed or classified simply as acute otitis media. Seasonal peaks in winter and early spring mirror the epidemiology of respiratory infections and acute otitis media. There is no significant gender predilection. The condition is more commonly diagnosed in primary care and pediatric settings than in otolaryngology clinics. | Can occur at any age but is most common in children aged 2-8 years, reflecting the peak incidence of acute otitis media in this age group. Adults are less frequently affected but can develop the condition at any age, particularly during upper respiratory infections or influenza epidemics. Elderly patients are occasionally affected, and cases associated with Mycoplasma pneumoniae infection tend to occur in adolescents and young adults (ages 10-30 years), corresponding to the peak age group for Mycoplasma respiratory infections. There is no significant age-related difference in clinical severity or outcomes. | Acute, severe otalgia (ear pain) is the hallmark symptom and is typically more intense than in uncomplicated acute otitis media, often causing significant distress particularly in young children. The pain is sharp, deep, and may radiate to the temporal region or jaw. Bloody (serosanguinous) otorrhea occurs when bullae rupture, which is characteristic of the condition and often provides dramatic pain relief. Hearing loss is present in the majority of patients, typically a mild-to-moderate conductive hearing loss (15-30 dB) from the bullae themselves and any concurrent middle ear effusion. Aural fullness and pressure are commonly reported. Systemic symptoms including low-grade fever, malaise, and concurrent upper respiratory symptoms (rhinorrhea, cough) are present in 50-60% of cases. On otoscopy, one or more hemorrhagic or serous bullae are visible on the tympanic membrane surface, ranging from small (2-3 mm) to large enough to fill the entire visualized field, and may extend to the adjacent deep canal skin. | Tympanic membrane (lateral surface, squamous epithelium); deep external auditory canal skin; middle ear (concurrent acute otitis media in 50-70% of cases) | Otoscopic examination is the primary diagnostic tool, revealing characteristic fluid-filled bullae on the tympanic membrane surface. Bullae appear as rounded, raised, translucent or hemorrhagic vesicles that may be single or multiple, ranging from amber (serous) to dark red (hemorrhagic). Pneumatic otoscopy should assess tympanic membrane mobility to evaluate for concurrent middle ear effusion (reduced mobility suggests associated acute otitis media). Tympanometry may show a Type B or Type C pattern when middle ear effusion is present. Audiometry reveals conductive hearing loss correlating with the degree of tympanic membrane compromise and middle ear involvement. Aspiration of bullae fluid (myringotomy with culture) is not routinely performed but can identify the causative organism for research purposes or refractory cases. Mycoplasma pneumoniae serology (IgM antibodies) or PCR may be considered when Mycoplasma is suspected clinically (concurrent atypical pneumonia). In recurrent or atypical cases, granular myringitis, tympanic membrane cholesteatoma, or middle ear neoplasm should be considered in the differential diagnosis. | Oral antibiotics targeting the same organisms as acute otitis media are recommended given the high rate of concurrent bacterial infection: amoxicillin 80-90 mg/kg/day in children (divided into 2-3 doses) or 875 mg twice daily in adults for 10 days is first-line therapy. For penicillin-allergic patients or treatment failures, amoxicillin-clavulanate 90 mg/kg/day (amoxicillin component) in children or 875/125 mg twice daily in adults, or azithromycin 10 mg/kg day 1 then 5 mg/kg/day for days 2-5. Analgesic therapy is essential given the severity of pain: ibuprofen 10 mg/kg every 6-8 hours in children or 400-600 mg every 6-8 hours in adults, combined with acetaminophen 15 mg/kg every 4-6 hours in children or 500-1000 mg every 6 hours in adults for multimodal pain control. Topical analgesic drops containing antipyrine/benzocaine (Auralgan) or 2% lidocaine may provide additional local pain relief applied to the tympanic membrane. Needle aspiration or myringotomy of large, tense bullae provides immediate pain relief and may be performed in the office under topical phenol anesthesia. Topical antibiotic drops (ciprofloxacin 0.3%/dexamethasone 0.1%) are applied after bulla rupture or aspiration to prevent secondary infection, 4 drops twice daily for 7 days. Warm compresses applied to the affected ear provide additional comfort. | Excellent prognosis with complete resolution in the vast majority of patients within 7-14 days. Bullae typically rupture spontaneously within 24-48 hours, often with dramatic pain relief. Hearing returns to baseline once the bullae resolve and any concurrent middle ear effusion clears, usually within 2-4 weeks. Complications are uncommon and include secondary bacterial infection of ruptured bullae, tympanic membrane perforation (which almost always heals spontaneously within 4-6 weeks), and rarely, granular myringitis if the tympanic membrane epithelium fails to regenerate normally. Sensorineural hearing loss has been reported in rare cases, particularly those associated with Mycoplasma pneumoniae, but is uncommon (<5%). Recurrence is unusual and should prompt evaluation for underlying eustachian tube dysfunction or immune deficiency. The condition does not lead to chronic ear disease in the vast majority of patients. | H73.019 |
| 4 | 3 | Cauliflower Ear | External Ear Disorders | Cauliflower ear (auricular hematoma with subsequent fibroneocartilage formation) results from blunt trauma to the auricle that shears the tightly adherent perichondrium from the underlying elastic cartilage, creating a subperichondrial hematoma. The auricular cartilage, being avascular, depends entirely on the overlying perichondrium for its blood supply via diffusion. When the perichondrium is separated by an expanding hematoma, the intervening cartilage becomes ischemic and undergoes necrosis. If the hematoma is not promptly evacuated, fibroblasts from the perichondrium and surrounding soft tissue invade the organized hematoma, depositing new fibrocartilage (neocartilage) and collagen in a disorganized pattern. This process, termed fibroneocartilage formation, obliterates the normal anatomic contours of the auricle, producing the characteristic thickened, nodular, deformed appearance. The anterior surface of the auricle is most vulnerable because the skin and perichondrium are thinnest and most tightly adherent to the cartilage in this region. Repeated episodes of trauma and hematoma formation, as occurs in contact sports, lead to progressive deformity. Secondary infection of an untreated auricular hematoma (suppurative perichondritis) can accelerate cartilage destruction and worsen the deformity. | Extremely common in contact sports, with prevalence rates of 44-84% among collegiate and professional wrestlers, 40-60% among mixed martial arts (MMA) fighters, and 20-40% among rugby forwards. The condition affects an estimated 5-10% of all contact sport athletes at some point during their careers. Population-wide prevalence data are limited because mild cases may not seek medical attention. In non-athletic contexts, auricular hematoma occurs in approximately 2-5 per 100,000 emergency department visits for facial trauma. Males are affected far more commonly than females (approximately 10:1), reflecting higher participation rates in high-risk contact sports. | Most commonly occurs in adolescents and young adults aged 15-35 years, corresponding to peak participation in contact sports such as wrestling, boxing, MMA, rugby, and judo. The condition can occur at any age with appropriate traumatic mechanism, including accidental falls, motor vehicle accidents, and physical assault. Pediatric cases in young wrestlers (ages 10-14) are well documented. Cumulative deformity worsens with continued sport participation, so severe cauliflower ear is typically seen in older, more experienced athletes. Occupational cases may occur in law enforcement and military personnel. | Acute auricular hematoma presents with rapid-onset swelling, ecchymosis, and fluctuance of the anterior auricular surface, typically within hours of the traumatic event. Pain ranges from mild to moderate, with tenderness on palpation and a sensation of fullness or pressure. The normal anatomic landmarks of the antihelix, scaphoid fossa, and triangular fossa become obscured by the expanding hematoma. If untreated, the acute hematoma organizes over 7-10 days, transitioning from a fluctuant collection to a firm, fibrotic mass. Established cauliflower ear deformity is characterized by a thickened, irregular, nodular auricle with loss of normal contours, a pale or discolored appearance, and a firm, non-tender consistency. Hearing is generally unaffected unless the deformity causes mechanical obstruction of the EAC or concurrent canal injury is present. | Auricle (pinna); auricular cartilage and perichondrium; external auditory canal (if deformity causes secondary obstruction) | Clinical diagnosis based on history of auricular trauma and physical examination revealing a fluctuant or firm swelling of the anterior auricular surface with loss of normal contour. Aspiration of the collection with an 18-gauge needle confirms the diagnosis when serosanguinous or hemorrhagic fluid is obtained. Ultrasound (high-frequency linear probe, 12-15 MHz) can accurately characterize the hematoma size, depth, and distinguish acute hematoma from organized fibrotic tissue or abscess. CT or MRI imaging is generally unnecessary for isolated auricular hematoma but may be indicated when concurrent temporal bone fracture or intracranial injury is suspected. In the chronic established deformity, the diagnosis is clinical based on the characteristic appearance and history. If abscess is suspected (fever, increasing erythema, fluctuance with purulent drainage), aspiration with Gram stain and culture is essential. | Acute auricular hematoma requires urgent drainage within 24-72 hours to prevent permanent deformity. Needle aspiration using an 18-gauge needle under sterile conditions may be attempted for small, acute hematomas, but incision and drainage is more definitive for larger or recurrent collections. A curvilinear incision along the antihelix is made, the hematoma is evacuated, and through-and-through mattress bolster sutures (dental rolls or silicone bolsters) using 4-0 nylon are placed to re-approximate the perichondrium to cartilage and prevent reaccumulation. Alternatively, quilting sutures without bolsters may be used. A compressive mastoid-type dressing is applied for 5-7 days. Prophylactic antibiotics covering skin flora and Pseudomonas are administered, such as cephalexin 500 mg four times daily or ciprofloxacin 500 mg twice daily for 7-10 days, given the risk of perichondritis. For established cauliflower ear deformity, surgical correction (otoplasty) involves excision of fibroneocartilage and recontouring using autologous cartilage grafts if needed, though results are often suboptimal for severely deformed ears. Prevention with properly fitted headgear (wrestling ear guards) is the most effective strategy. | Prognosis for preventing deformity is excellent when drainage is performed within 24 hours of injury, with successful prevention of cauliflower ear in more than 90% of promptly treated cases. Delayed treatment beyond 48-72 hours significantly reduces the likelihood of preventing permanent deformity, as fibroblast proliferation and collagen deposition begin within 2-3 days. Recurrence of hematoma after drainage occurs in 10-20% of cases and may require repeat drainage. Infection (suppurative perichondritis) complicates 3-8% of auricular hematomas and dramatically worsens cartilage destruction and subsequent deformity. Once established cauliflower ear deformity has formed, it is permanent without surgical correction, and even surgical reconstruction rarely achieves a completely normal appearance. Athletes who return to contact sports without protective headgear have a high likelihood of recurrent trauma and progressive deformity. | M95.10 |
| 5 | 4 | Cerumen Impaction | External Ear Disorders | Cerumen (earwax) impaction occurs when accumulated cerumen fully occludes the external auditory canal, causing symptoms and/or preventing adequate examination of the tympanic membrane. Cerumen is a normal secretion produced by ceruminous glands (modified apocrine sweat glands) and sebaceous glands in the cartilaginous outer third of the EAC, composed of a mixture of desquamated keratinocytes (60%), saturated and unsaturated long-chain fatty acids, squalene, cholesterol, and antimicrobial peptides (lysozyme, lactoferrin) that provide a protective acidic (pH 6.1) barrier. The normal self-cleaning mechanism relies on lateral epithelial migration from the tympanic membrane outward (at approximately 0.05 mm/day) combined with jaw movement during mastication, which propels cerumen toward the canal entrance. Impaction results when this self-cleaning mechanism is disrupted by factors including: narrow or tortuous ear canals (anatomic variation or exostoses), excessive cerumen production (genetic, hormonal), insertion of cotton swabs or hearing aids that push cerumen deeper, canal obstruction (exostoses, osteomas, canal stenosis), increased keratin content in elderly patients producing harder, drier cerumen, and hearing aid or earplug use that blocks normal outward migration. Cerumen exists in two phenotypic forms determined by the ABCC11 gene: wet cerumen (golden-brown, sticky; predominant in Caucasian and African populations) and dry cerumen (gray, flaky; predominant in East Asian and Native American populations). | One of the most common conditions in otologic practice, affecting approximately 6% of the general population at any given time and up to 10% of children. Approximately 12 million people seek medical care for cerumen impaction annually in the United States, generating over 8 million cerumen removal procedures per year. Prevalence is significantly higher in certain populations: 30-40% of elderly individuals in care facilities, 30-36% of patients with intellectual disabilities, 20-25% of hearing aid users, and 10-15% of children. The condition accounts for approximately 25% of all primary care ear-related visits. Males are slightly more frequently affected than females. Annual healthcare costs attributable to cerumen impaction in the US are estimated at $47 million for office visits alone. | Occurs at all ages, from neonates to the elderly. Children aged 2-10 years are commonly affected due to narrower ear canals and difficulty with hygiene. A second peak occurs in patients over 65 years, where cerumen becomes drier and harder due to decreased glandular secretion, and the ear canal narrows with aging cartilage changes. Hearing aid use in the elderly population further increases impaction rates. In neonates, vernix caseosa may mimic cerumen impaction. Occupational exposure to dust and debris (construction workers, miners) increases impaction risk in working-age adults. | Conductive hearing loss is the most common symptom, typically mild (5-15 dB) but occasionally significant (up to 40 dB) when the canal is completely occluded, and often perceived as sudden when the final increment of cerumen completes the occlusion (e.g., after swimming when cerumen swells with water absorption). Aural fullness, pressure, or a sensation of ear blockage is reported by the majority of patients. Tinnitus (ringing, buzzing, or humming) accompanies hearing loss in 30-40% of cases. Otalgia (ear pain) may occur from pressure of impacted cerumen against the canal walls or tympanic membrane, and pain during jaw movement can mimic temporomandibular joint dysfunction. Pruritus (itching) is common, particularly with dry cerumen types. Dizziness or vertigo may rarely result from cerumen impaction, possibly from pressure changes on the tympanic membrane or caloric stimulation by hard cerumen abutting the canal wall near the tympanic membrane. Cough (Arnold nerve reflex) may be triggered by cerumen stimulating the auricular branch of the vagus nerve. | External auditory canal; tympanic membrane (secondary effects from pressure or inability to examine) | Otoscopic examination reveals a mass of cerumen partially or completely occluding the EAC, preventing visualization of the tympanic membrane. The cerumen may range from soft and golden-brown to hard, dark, and rock-like depending on age and composition. Audiometry should be performed before and after removal if hearing loss is a concern, typically showing a low-frequency conductive hearing loss pattern. Tympanometry may show a flat (Type B) tympanogram when cerumen fully occludes the canal, which normalizes after removal (a useful tool if middle ear effusion must be excluded). After removal, complete otoscopic examination of the tympanic membrane is essential to exclude underlying pathology (perforation, cholesteatoma, middle ear effusion). No imaging or laboratory studies are necessary for uncomplicated cerumen impaction. If the cerumen is hard, adherent, and the tympanic membrane cannot be visualized, cerumenolytic agents should be applied for softening before attempted removal. | Three principal methods exist for cerumen removal, chosen based on cerumen consistency, canal anatomy, and provider expertise. Manual removal under direct otoscopic or microscopic visualization using curettes (Jobson-Horne, Shapleigh), alligator forceps, or right-angle hooks is the most precise method and is preferred for hard, impacted cerumen and when the tympanic membrane status is uncertain. Irrigation (warm water at body temperature 37 degrees Celsius, using a 20-60 mL syringe with a soft catheter tip or electronic pulsed irrigation device) is effective for soft cerumen; contraindicated if tympanic membrane perforation is suspected, tympanostomy tubes are present, or prior mastoid surgery has been performed. Cerumenolytic agents soften hard cerumen prior to removal: docusate sodium 0.5% (Debrox alternative), hydrogen peroxide 3% drops, carbamide peroxide 6.5% (Debrox) 5-10 drops for 15-30 minutes, or sodium bicarbonate 10% drops. Olive oil or mineral oil drops (5 drops at bedtime for 3-5 nights) are gentle softeners for at-home pre-treatment. Microsuction under microscopic visualization is safe and precise, particularly suitable for patients with tympanic membrane perforations, narrow canals, or previous surgery. Post-removal, acidifying drops (acetic acid 2%) may be applied to restore normal canal pH. Patient education on avoiding cotton swab insertion is essential for prevention. | Excellent prognosis following successful cerumen removal, with immediate symptom resolution in more than 95% of cases. Hearing typically returns to baseline immediately after complete removal. Complications of cerumen removal are uncommon (1-5%) and include canal skin abrasion, tympanic membrane perforation (0.01-0.5% with irrigation), otitis externa from irrigation-induced moisture, vertigo from caloric stimulation during irrigation, and vasovagal syncope. Recurrence is the main long-term issue, with 30-40% of patients experiencing repeat impaction within 12 months, particularly in predisposed individuals (hearing aid users, anatomic variants, elderly). Regular professional cleaning every 6-12 months may be recommended for recurrence-prone patients. Self-cleaning with cotton swabs should be strongly discouraged as it worsens impaction. Over-the-counter cerumenolytic drops used prophylactically (weekly) may reduce recurrence frequency. | H61.20 |
| 6 | 5 | Contact Dermatitis of the Ear | External Ear Disorders | Contact dermatitis of the ear encompasses both allergic contact dermatitis (ACD, type IV delayed hypersensitivity reaction) and irritant contact dermatitis (ICD) affecting the auricle and external auditory canal. Allergic contact dermatitis is mediated by sensitized T lymphocytes (CD4+ Th1 cells) that recognize hapten-protein conjugates presented by Langerhans cells, triggering an inflammatory cascade upon re-exposure, with a latency period of 24-72 hours. The most common allergens causing auricular ACD include nickel sulfate (the most prevalent contact allergen worldwide, found in earrings, hearing aids, and spectacle frames), cobalt chloride, chromium, neomycin (present in many otic drops), benzocaine, propylene glycol (vehicle in otic preparations), fragrances, and rubber components in hearing aid molds and earplugs. Irritant contact dermatitis results from direct cytotoxic damage to the skin barrier by chemical irritants without prior sensitization, commonly from hearing aid materials, prolonged moisture, antiseptic solutions (chlorhexidine, alcohol), or strong topical medications. The thin skin of the EAC and conchal bowl is particularly susceptible to contactants due to its limited barrier function. Chronic contact dermatitis leads to epidermal thickening (lichenification), fissuring, and secondary bacterial or fungal colonization, perpetuating the inflammatory cycle. | Contact dermatitis is one of the most common dermatologic conditions affecting the ear. Nickel allergy affects approximately 10-15% of the general population (up to 25-30% of women with pierced ears) and is the most common cause of earring-related dermatitis. Hearing aid-related contact dermatitis affects 15-30% of hearing aid users, with acrylates, silicone, and methacrylate being common sensitizers in hearing aid mold materials. Neomycin allergy is present in approximately 10-18% of patients with chronic otitis externa, making it one of the most frequently encountered medication allergies in otologic practice. The overall prevalence of otic topical medication allergy among chronic otitis externa patients is 20-40%. Contact dermatitis of the EAC accounts for approximately 10-15% of all chronic otitis externa cases. Women are affected more frequently than men for earring-related dermatitis due to higher piercing rates. | Can occur at any age, with the pattern depending on the specific allergen. Earring-related nickel dermatitis most commonly presents in adolescents and young women (ages 12-30) following ear piercing. Hearing aid-related contact dermatitis predominantly affects elderly patients (over 65 years) who are the primary hearing aid users. Neomycin and other topical medication allergies can develop at any age but are more common in adults with chronic ear conditions requiring prolonged topical therapy. Occupational contact dermatitis (hairdressers, healthcare workers) follows occupational exposure patterns. Sensitization typically requires prior exposure, so first episodes occur months to years after initial contact with the allergen. | Pruritus is the hallmark symptom and is often intense, leading to scratching that exacerbates the condition. Acute allergic contact dermatitis presents with erythema, edema, vesiculation, and weeping of the affected skin, localized to the area of allergen contact (earlobes from earrings, conchal bowl from hearing aids, EAC from otic drops). The rash typically has well-demarcated borders corresponding to the shape of the contactant. Chronic contact dermatitis manifests as dry, scaly, thickened (lichenified) skin with fissuring, particularly in the retroauricular sulcus and at the EAC entrance. Secondary bacterial infection may cause purulent discharge, crusting, and increased pain. Eczematous changes in the EAC can cause conductive hearing loss from canal wall edema and accumulated debris. A burning sensation may accompany irritant contact dermatitis more than allergic contact dermatitis. | Auricle (earlobe, conchal bowl, helix); external auditory canal; retroauricular sulcus; periauricular skin | Patch testing is the gold standard for identifying the specific causative allergen in suspected allergic contact dermatitis, performed by a dermatologist using standardized allergen panels (TRUE test or extended series). The standard series includes nickel sulfate, neomycin, fragrance mix, balsam of Peru, rubber accelerators, preservatives, and other common allergens, applied on the upper back for 48 hours with readings at 48 and 96 hours. Clinical history correlating symptom onset with specific exposures (new earrings, hearing aid use, otic drops) is essential. Otoscopic examination reveals erythematous, edematous, scaly, or weeping EAC skin, often with a clear demarcation at the point of contact. Skin biopsy is rarely needed but shows spongiotic dermatitis with eosinophils in acute ACD and acanthosis with hyperkeratosis in chronic ACD. Culture of any secondary infection guides antibiotic selection. Serum IgE levels are typically normal (contact dermatitis is a type IV, not type I, reaction). KOH preparation should be performed to exclude concurrent fungal infection. | Identification and strict avoidance of the causative allergen is the cornerstone of treatment and prevention. For acute flares, moderate-potency topical corticosteroids such as betamethasone valerate 0.1% cream or triamcinolone acetonide 0.1% cream applied twice daily for 2-3 weeks to the auricle, or fluocinolone acetonide 0.01% oil-based drops for EAC involvement. For severe acute reactions, a short course of oral prednisone 40-60 mg daily for 5-7 days with rapid taper may be required. Topical calcineurin inhibitors (tacrolimus 0.1% ointment or pimecrolimus 1% cream twice daily) are useful for maintenance therapy and steroid-sparing management on the thin auricular skin. Emollients and barrier creams (dimethicone-based) protect the skin and restore the epidermal barrier. Antihistamines such as cetirizine 10 mg daily or hydroxyzine 25 mg at bedtime provide symptomatic relief of pruritus. For nickel allergy, switching to hypoallergenic jewelry (titanium, surgical steel, 14k+ gold, or platinum) is essential. Hearing aid-related dermatitis may require refabrication of the mold using a non-sensitizing material (silicone, titanium, or hypoallergenic acrylic). Secondary bacterial infection requires topical or systemic antibiotic treatment. | Excellent prognosis when the causative allergen is identified and successfully avoided, with complete resolution expected within 2-4 weeks of cessation of exposure. Without allergen avoidance, the condition will persist or recur with each exposure. Chronic contact dermatitis that has been present for months to years may take 4-8 weeks to fully resolve even after allergen elimination. Secondary skin changes (lichenification, hyperpigmentation) may persist for months after active inflammation resolves. Approximately 80-90% of patients can identify and avoid their specific triggers with patch testing guidance. Patients sensitized to one allergen have a higher risk of developing sensitivity to other allergens over time (cross-sensitization or polysensitization occurs in 15-20%). Permanent hearing aid-related dermatitis may necessitate bone-anchored hearing devices as an alternative. Quality of life impact is significant but fully reversible with appropriate management. | L23.89 |
| 7 | 6 | Eczematous Otitis Externa | External Ear Disorders | Eczematous otitis externa refers to inflammatory dermatitis of the external auditory canal and auricle associated with underlying eczematous skin conditions, most commonly atopic dermatitis, seborrheic dermatitis, and psoriasis. In atopic dermatitis (the most frequent underlying condition), skin barrier dysfunction due to filaggrin gene mutations and reduced ceramide production leads to increased transepidermal water loss, enhanced allergen penetration, and susceptibility to Staphylococcus aureus colonization (present in 90% of atopic patients). Seborrheic dermatitis of the EAC involves hypersensitivity to Malassezia furfur (Pityrosporum ovale) commensal yeast, triggering inflammation in sebum-rich areas including the conchal bowl and retroauricular sulcus. Psoriatic involvement of the ear affects 18-50% of psoriasis patients and represents an extension of scalp psoriasis along the hairline to the retroauricular area, conchal bowl, and EAC. The EAC skin is continuous with the auricle and periauricular skin, so dermatologic conditions affecting these areas commonly extend into the canal. The impaired skin barrier in all eczematous conditions predisposes to secondary bacterial infection (acute infectious otitis externa) and fungal overgrowth (otomycosis), creating a cycle of inflammation, infection, and further barrier disruption. Neurodermatitis (lichen simplex chronicus) of the EAC, caused by chronic scratching and rubbing, may complicate any form of eczematous otitis externa. | Atopic dermatitis affects approximately 10-20% of children and 2-5% of adults, with ear involvement reported in 15-40% of atopic patients. Seborrheic dermatitis affects 3-5% of the general population, with ear involvement in 20-30% of affected individuals. Psoriasis affects approximately 2-3% of the population, with ear involvement in 18-50% of psoriasis patients. Eczematous otitis externa collectively represents 15-25% of all chronic otitis externa cases seen in otolaryngology clinics. The condition is more common in temperate climates with low humidity and during winter months when dry air exacerbates eczematous conditions. There is a slight female predominance in atopic-related cases. | Age of onset depends on the underlying eczematous condition. Atopic dermatitis typically begins in infancy or early childhood (60% by age 1, 85% by age 5), so ear involvement may present from early childhood through adulthood. Seborrheic dermatitis has a bimodal distribution, affecting infants (cradle cap, typically resolving by age 1) and adults (peak incidence ages 30-60). Psoriatic ear involvement typically presents after the onset of cutaneous psoriasis, most commonly between ages 15 and 35 for the first episode. Asteatotic eczema (dry skin-related) predominantly affects elderly patients (over 65 years) due to decreased sebaceous gland activity. | Intense pruritus of the EAC and auricle is the dominant symptom, often prompting habitual scratching, rubbing, or insertion of cotton swabs, hairpins, and other instruments that further damage the canal skin. The canal skin appears erythematous, dry, scaly, and may show fissuring, particularly at the EAC entrance and in the retroauricular sulcus. In seborrheic dermatitis, greasy, yellowish scales are characteristic, often extending from the scalp over the posterior auricular skin and conchal bowl. In psoriasis, well-demarcated, silvery-white, thick, adherent plaques are seen on the auricle, retroauricular area, and may extend into the EAC. Chronic changes include canal skin thickening (acanthosis), lichenification from repeated scratching, and narrowing of the EAC lumen from chronic edema and fibrosis. Secondary bacterial or fungal infection superimposed on the eczematous base causes increased pain, purulent or malodorous discharge, and worsening symptoms. | External auditory canal; auricle (conchal bowl, antihelix, lobule); retroauricular sulcus; periauricular skin; tympanic membrane (may show myringitis or secondary changes) | Clinical diagnosis based on characteristic dermatologic findings on otoscopy and physical examination, correlated with history of known eczematous skin condition or family history of atopy. Otoscopy reveals diffuse erythema, scaling, and crusting of the EAC skin with variable edema, distinguishable from infectious otitis externa by the absence of profuse purulent otorrhea and the presence of typical eczematous morphology. Skin prick testing or specific IgE levels may identify atopic sensitizations in patients with suspected atopic dermatitis. Fungal cultures or KOH preparation of canal debris should be performed when otomycosis is suspected. Bacterial culture is indicated when secondary infection is present. Biopsy of atypical or treatment-resistant lesions is performed to exclude malignancy (squamous cell carcinoma of the EAC) and confirm the eczematous diagnosis (showing spongiosis, acanthosis, and mixed inflammatory infiltrate). Audiometry is indicated if hearing loss is reported. Screening for psoriatic arthritis (joint symptoms, nail changes) should be performed in psoriatic ear involvement. | Treatment addresses both the acute inflammation and the underlying chronic skin condition. Topical corticosteroids are first-line: hydrocortisone 1% cream for mild cases, betamethasone valerate 0.1% or fluocinolone acetonide 0.01% oil-based otic drops for moderate EAC involvement, applied 2-3 drops twice daily for 2-4 weeks, then tapered to the lowest effective potency and frequency for maintenance. For seborrheic dermatitis, antifungal agents targeting Malassezia are added: ketoconazole 2% cream applied to auricular skin twice daily, or clotrimazole 1% solution 3-4 drops in the EAC twice daily for 2-4 weeks. Topical calcineurin inhibitors (tacrolimus 0.1% ointment or pimecrolimus 1% cream) are excellent steroid-sparing maintenance agents, particularly for periauricular skin. Regular emollient application (ceramide-containing moisturizers) to the auricle and EAC entrance restores barrier function. For psoriatic involvement, calcipotriol 0.005% ointment applied once daily may be used in combination with topical corticosteroids. Aural toilet with gentle suctioning removes accumulated scales and debris. Secondary bacterial infection requires topical antibiotic-steroid combination drops (ciprofloxacin/dexamethasone). Systemic therapy for severe, refractory eczematous otitis externa follows guidelines for the underlying condition (dupilumab for atopic dermatitis, biologics for psoriasis). | Chronic, relapsing course that mirrors the natural history of the underlying eczematous condition. Complete cure is uncommon, but symptoms can be well controlled in 80-90% of patients with appropriate topical therapy and maintenance regimens. Flares are expected and correlate with systemic disease activity, environmental triggers (dry cold weather, allergen exposure), and periods of medication non-compliance. Secondary infection complicates 20-30% of flares and may require additional antibiotic therapy. Long-term topical corticosteroid use on the thin canal skin carries risks of skin atrophy, telangiectasia, and increased infection susceptibility, necessitating judicious use and steroid-sparing alternatives. Chronic eczematous otitis externa may lead to EAC stenosis in 5-10% of long-standing cases. Hearing loss is usually mild and reversible with treatment of the canal inflammation and debris clearance. Quality of life impact is significant due to chronic pruritus and the need for ongoing medical management. | H60.549 |
| 8 | 7 | Exostosis (Surfer's Ear) | External Ear Disorders | Exostoses of the external auditory canal are benign, broad-based bony growths arising from the tympanic bone in response to chronic cold water and wind exposure. The pathogenesis involves periosteal stimulation by repeated cold water exposure (typically below 19 degrees Celsius), triggering osteoblastic activity and new lamellar bone deposition in the deep bony EAC. The growths are typically bilateral and multiple, arising from the tympanomastoid and tympanosquamous suture lines of the bony canal. Histologically, exostoses consist of dense, compact lamellar bone with minimal marrow spaces, covered by normal canal skin periosteum. The condition develops gradually over 5-10 years of regular cold water exposure, with the rate of growth proportional to the frequency, duration, and temperature of water exposure. Wind chill effect significantly accelerates exostosis formation, as evaporative cooling of wet ear canals drops the periosteal temperature below that of the water alone. The genetic predisposition is suggested by the observation that not all equally exposed individuals develop exostoses to the same degree, though specific genetic markers have not been identified. Exostoses differ from osteomas in that they are sessile (broad-based), multiple, and always arise from the bony EAC medially. | Extremely common among cold-water surfers, with prevalence ranging from 38-80% depending on years of exposure, water temperature, and geographic location. Studies in Northern California, Oregon, and United Kingdom surf populations demonstrate prevalence rates of 61-73%. Prevalence correlates directly with cumulative exposure: 38% in surfers with less than 5 years of experience versus 80% in those with more than 10 years. The condition also affects cold-water swimmers, divers, kayakers, and sailors at lower but significant rates (15-25%). Overall prevalence in the general non-water-sports population is estimated at 1-6%. Males are affected 2-3 times more frequently than females, reflecting higher participation rates in cold-water sports rather than inherent biological susceptibility. | Typically develops after years of cumulative cold water exposure, with initial bony changes detectable as early as the mid-20s in dedicated surfers who began in childhood. Clinically significant exostoses causing symptoms are most commonly diagnosed between ages 30 and 50 years. Pediatric cases are uncommon but have been reported in children as young as 12 years with intensive cold-water exposure histories. The condition is progressive and does not regress spontaneously, so age at diagnosis depends on the threshold of obstruction causing symptoms and the onset age of cold-water activity. | Many patients are asymptomatic until exostoses occlude more than 60-80% of the EAC lumen. Recurrent otitis externa is the most common presenting complaint, occurring because retained water and debris behind the bony obstruction create a favorable environment for infection. Progressive conductive hearing loss develops as the canal narrows, typically mild (10-25 dB air-bone gap). Cerumen impaction becomes frequent and problematic as self-cleaning mechanisms of the canal are disrupted. A sensation of aural fullness, water trapping with persistent moisture in the ear after swimming, and tinnitus may be reported. In advanced cases with near-complete canal occlusion, patients may experience significant hearing difficulty and chronic otorrhea from persistent infection behind the obstruction. | External auditory canal (tympanic bone); tympanic membrane (secondarily affected by retained debris and infection) | Otoscopic examination reveals smooth, broad-based, skin-covered bony growths in the deep bony EAC, typically located anteriorly, posteriorly, and superiorly, often with a narrow residual canal lumen. High-resolution CT of the temporal bones without contrast is the gold standard for grading severity, demonstrating dense bony growths with no internal soft tissue or marrow component, and precisely quantifying the degree of canal occlusion. Grading systems classify exostoses as Grade I (<33% occlusion), Grade II (33-66% occlusion), or Grade III (>66% occlusion). Audiometry should be performed to document baseline hearing and quantify any conductive hearing loss. Microscopic examination is essential to assess the relationship of exostoses to the tympanic membrane and to distinguish from osteoma or malignancy. Clinical history of cold-water exposure is a critical diagnostic clue, and bilateral involvement strongly supports the diagnosis. | Conservative management is appropriate for asymptomatic or mildly symptomatic patients and includes water precautions with custom-fitted earplugs during water sports, regular aural toilet by a specialist, and acidifying drops (acetic acid 2%) after water exposure. Surgical canalplasty is indicated when exostoses cause recurrent infections (3 or more episodes per year), significant conductive hearing loss, inability to adequately examine the tympanic membrane, or failed conservative measures. The standard surgical approach is via a transcanal or postauricular route using a high-speed otologic drill (diamond burrs) with continuous irrigation to prevent thermal injury to the facial nerve and tympanic membrane. Chisels (osteotomes) may be used as an alternative or adjunct, particularly for exostoses near the tympanic membrane where drilling carries higher risk. Postoperative care includes packing with antibiotic-soaked Gelfoam or silastic sheeting for 2-3 weeks, topical antibiotic drops (ciprofloxacin/dexamethasone) for 2-4 weeks, and strict water avoidance for 6-8 weeks. Continued cold-water exposure without ear protection after surgery leads to recurrence in up to 15-20% of cases over 5-10 years. | Excellent prognosis with surgical canalplasty, with hearing improvement and resolution of recurrent infections in 90-95% of patients. Surgical complications include EAC stenosis (5-10%), tympanic membrane perforation (1-3%), sensorineural hearing loss (rare, <1%), facial nerve injury (exceedingly rare, <0.5%), and canal skin lacerations requiring prolonged healing. Recurrence after surgery occurs in 5-15% of patients if cold-water exposure continues without adequate ear protection, but is uncommon (<5%) in those who use protective earplugs. The condition is entirely preventable with consistent use of well-fitting earplugs and neoprene hoods during cold-water activities. Without treatment, exostoses are slowly progressive and may eventually cause complete canal obstruction. | H61.819 |
| 9 | 8 | External Auditory Canal Cholesteatoma | External Ear Disorders | External auditory canal cholesteatoma (EACC) is a rare, locally aggressive condition characterized by focal invasion of squamous keratinizing epithelium into the bony canal wall, causing progressive bone erosion and sequestration. Unlike keratosis obturans, which involves diffuse keratin accumulation, EACC features a focal area of periostitis and bone necrosis with invasion of keratinized epithelium into the defect. The pathogenesis may be primary (spontaneous) or secondary to trauma, surgery, or chronic otitis externa that disrupts the normal canal epithelium and exposes the underlying periosteum. In the primary form, focal ischemic necrosis of the bony canal (possibly related to microangiopathy or periostitis) creates a defect that is then colonized by migrating squamous epithelium. The process is analogous to middle ear cholesteatoma, with the accumulating keratin and enzymatic bone erosion (mediated by collagenase, metalloproteinases, and cytokines from the cholesteatoma matrix) causing progressive destruction of the bony canal. Involvement of the tympanic bone inferiorly is most common, with potential extension into the mastoid, middle ear, or temporomandibular joint. The condition is unilateral in the vast majority of cases, distinguishing it from keratosis obturans. | Rare condition, estimated to represent 0.1-0.5% of all cases of otitis externa and approximately 1 per 1,000 otologic clinic patients. Large tertiary otologic referral centers report 2-5 cases annually. The true prevalence may be underestimated because mild cases may be misdiagnosed as chronic otitis externa or cerumen impaction. Secondary EACC following ear surgery or trauma may be more common than the spontaneous primary form. There is no clear racial, ethnic, or geographic predilection. The condition is significantly less common than middle ear cholesteatoma. | Primarily affects older adults, with mean age at diagnosis of 55-65 years, contrasting with the younger age distribution of keratosis obturans. Most patients are diagnosed between ages 40 and 75 years. The older age of onset in the primary form may relate to age-related changes in canal bone vascularity and periosteal vitality. Secondary EACC can occur at any age following the inciting event (trauma, surgery, radiation therapy). Pediatric cases are exceedingly rare and are nearly always secondary to prior otologic surgery or trauma. | Persistent, dull, deep-seated otalgia is the most common presenting symptom, often insidious in onset and gradually progressive over months to years. Unilateral foul-smelling otorrhea, often with small amounts of keratinous debris, is present in the majority of cases. Conductive hearing loss is variable and depends on the degree of canal obstruction and potential involvement of the middle ear. On otoscopic examination, a localized area of keratinous debris or granulation tissue is seen overlying a focal defect in the canal floor or posterior wall, often with sequestrated bone visible at the base. Unlike keratosis obturans, the canal is not diffusely widened; instead, focal bone erosion and a pocket or cavity in the canal wall are characteristic. Facial nerve involvement with ipsilateral facial weakness may occur when erosion extends to the fallopian canal, though this is rare. | External auditory canal (bony portion, predominantly inferior wall); temporal bone; mastoid; middle ear (in advanced cases); temporomandibular joint; facial nerve (rare) | High-resolution CT of the temporal bones is the most important diagnostic study, demonstrating a focal soft tissue mass in the EAC associated with underlying bone erosion, sequestration, or cavity formation in the bony canal wall, distinguishing EACC from keratosis obturans (diffuse canal widening) and neoplasm. MRI with diffusion-weighted imaging (DWI) helps distinguish cholesteatoma (restricted diffusion, bright on DWI) from granulation tissue, retained secretions, or tumor. Microscopic otoscopy reveals a focal area of keratinous debris or granulation tissue with an underlying bony defect, and probing may reveal a cavity extending into the bone. Histopathologic examination of debrided material confirms the presence of keratinized stratified squamous epithelium with a laminated keratin plug (cholesteatoma matrix and perimatrix). Audiometry documents the degree of conductive hearing loss. Culture of any purulent drainage guides antibiotic therapy for secondary infection. Staging systems (Naim or Holt) grade EACC by extent: limited to canal, extended to mastoid, or involving middle ear structures. | Surgical excision is the definitive treatment for EACC, as conservative management alone has high recurrence rates. Limited disease confined to the canal may be managed with transcanal excision (canalplasty) using curettage and drilling to remove the cholesteatoma sac and all involved bone until healthy, bleeding bone is reached. Extensive disease with mastoid involvement requires canal wall-down mastoidectomy (modified radical mastoidectomy) with wide exposure and complete exteriorization of the cholesteatoma cavity. Reconstruction of the canal defect may be performed using cartilage grafts (tragal or conchal cartilage), bone pate, or hydroxyapatite cement. Preoperative and postoperative topical antibiotic-steroid drops (ciprofloxacin 0.3%/dexamethasone 0.1%, 4 drops twice daily for 2-4 weeks) manage secondary infection and inflammation. Systemic antibiotics such as amoxicillin-clavulanate 875/125 mg twice daily for 7-14 days are used when cellulitis or deep infection accompanies the cholesteatoma. Regular postoperative surveillance with microscopic examination and periodic CT or MRI-DWI is essential to detect recurrence. | Prognosis depends on the extent of disease at diagnosis and completeness of surgical excision. Limited disease confined to the canal has a recurrence rate of 5-15% after adequate canalplasty. Extensive disease requiring mastoidectomy has higher recurrence rates of 15-30%, particularly when complete excision of the cholesteatoma matrix is difficult due to anatomic constraints. Long-term follow-up for at least 3-5 years with serial imaging is recommended due to the risk of late recurrence. Hearing outcomes are generally good when the middle ear is not involved, with closure of the air-bone gap in 70-80% of cases. Complications of advanced untreated EACC include mastoiditis, facial nerve palsy, labyrinthine fistula, sigmoid sinus thrombosis, and rarely intracranial extension. The condition does not undergo malignant transformation. | H60.40 |
| 10 | 9 | Foreign Body in Ear Canal | External Ear Disorders | Foreign body in the external auditory canal is a common emergency presentation involving the lodging of an exogenous object within the EAC. Foreign bodies are broadly categorized as organic (insects, seeds, beans, food particles, cotton tips, paper), inorganic (beads, toy parts, button batteries, stones, erasers, pieces of hearing aids), and animate (live insects, most commonly cockroaches, moths, ants, and beetles). In children, deliberate self-insertion of small objects during play is the predominant mechanism, while in adults, retained cotton swab tips, hearing aid components, and insect intrusion are most common. Button battery foreign bodies represent a true otologic emergency because the battery generates an external current when in contact with moist tissue, producing sodium hydroxide through electrolysis that causes liquefactive necrosis of the canal skin, tympanic membrane, and potentially deeper structures within 1-2 hours. Organic foreign bodies (seeds, beans) may swell with moisture absorption, making delayed removal progressively more difficult. Live insects cause extreme distress from buzzing, movement, and pain, and their attempts to burrow deeper can traumatize the delicate canal skin and tympanic membrane. Hygroscopic foreign bodies (peas, beans, sponge material) expand when irrigated with water, contraindicating irrigation as a removal technique. | One of the most common pediatric ENT emergencies, accounting for 6-8% of all pediatric emergency department visits in ENT-related complaints. Approximately 750,000-1,000,000 cases occur annually in the United States. Children between 2-8 years account for approximately 70-80% of all ear foreign body presentations. Insect foreign bodies predominate in adults, accounting for 14-30% of adult ear foreign body cases. Button batteries account for approximately 1-2% of all ear foreign bodies but represent a disproportionate share of morbidity. Bilateral foreign bodies are found in 5-10% of pediatric cases. Recurrence (repeat foreign body insertion) occurs in 5-15% of children, suggesting behavioral factors. There is a slight male predominance in the pediatric population (1.5:1 male-to-female ratio). | Bimodal age distribution with a sharp peak at ages 2-8 years (predominantly self-inserted objects during play) and a smaller peak in adults aged 20-60 years (insects, hearing aid components, cotton tips). In the pediatric population, the peak incidence is at ages 2-4 years, when children are most exploratory and have the manual dexterity to insert small objects but lack the judgment to refrain. Children under age 2 rarely present because they typically lack the fine motor skills to insert objects. Elderly patients may present with retained hearing aid dome tips or batteries. Live insect foreign bodies can occur at any age, with outdoor sleeping and camping increasing exposure. | Symptoms depend on the nature of the foreign body and the duration of retention. Asymptomatic cases, particularly smooth inert objects in children, may be discovered incidentally during routine otoscopic examination. Otalgia (ear pain) is the most common presenting symptom, resulting from pressure on the sensitive canal skin. Hearing loss occurs when the foreign body obstructs the canal lumen. Live insects cause intense acute distress with buzzing, scratching sensations, pain, and reflexive head-shaking or ear-rubbing, often waking the patient from sleep. Otorrhea (purulent or bloody discharge) develops with prolonged retention or traumatic impaction, indicating canal skin or tympanic membrane injury. Button batteries cause rapid-onset severe pain, bloody otorrhea, and may produce visible burns on the canal skin or tympanic membrane. Vertigo or nystagmus may result from caloric stimulation if a cool object contacts the tympanic membrane or from tympanic membrane perforation. Reflex cough (Arnold nerve reflex) can be triggered by vagal nerve stimulation from the foreign body. | External auditory canal; tympanic membrane (may be perforated by foreign body or by button battery corrosion); middle ear (if penetrating perforation occurs) | Otoscopic examination or examination with the operating microscope is the primary diagnostic method, directly visualizing the foreign body, its size, shape, position relative to the tympanic membrane, and any associated canal or tympanic membrane injury. Examination should assess whether the foreign body is medial or lateral to the isthmus (the narrowest point of the bony-cartilaginous junction), as objects medial to the isthmus are more difficult to remove and have higher complication rates. Bilateral ear examination is essential in children, as 5-10% have bilateral foreign bodies. Anterior rhinoscopy should also be performed to check for concurrent nasal foreign bodies. If the foreign body cannot be visualized due to canal edema or debris, CT temporal bone may be required, particularly for suspected button batteries (which appear as a double-ring sign on imaging). Audiometry is performed after removal if hearing concerns persist. Post-removal otoscopic examination of the tympanic membrane and canal skin is mandatory to document any injury. | Treatment approach depends on the type of foreign body, patient cooperation, and provider experience. For live insects, the first step is killing the insect with mineral oil, lidocaine 2% drops, or alcohol drops (5-10 drops, wait 2-3 minutes) to stop movement before attempting removal, which dramatically reduces patient distress. For inert, smooth objects: irrigation with warm water (37 degrees Celsius) using a syringe (contraindicated for batteries, organic/hygroscopic materials, or suspected TM perforation); manual removal with alligator forceps, right-angle hooks, curettes, or Katz extractors under microscopic guidance; or suction-tip removal for smooth round objects. Button batteries require immediate removal (within 1-2 hours) as an emergency due to rapid tissue necrosis; irrigation is absolutely contraindicated. In cooperative adults, office removal under topical anesthesia (phenol-soaked cotton or 4% lidocaine drops) is usually successful. Uncooperative children and deeply impacted objects may require removal under general anesthesia in the operating room, accounting for 10-30% of pediatric cases. Post-removal treatment includes antibiotic-steroid drops (ciprofloxacin 0.3%/dexamethasone 0.1% twice daily for 5-7 days) if canal abrasion or edema is present. Failed first attempts significantly increase complication rates, so referral to an otolaryngologist is recommended when primary care providers are unable to achieve removal. | Excellent prognosis for the vast majority of ear foreign bodies when removed promptly and atraumatically, with complete resolution of symptoms in over 95% of uncomplicated cases. Complications of foreign body removal include canal skin lacerations (10-20% of cases), tympanic membrane perforation (1-3%), otitis externa (5-10%), and rarely, ossicular chain disruption. Failed first attempts (by non-specialist providers) increase complication rates 5-10 fold and increase the likelihood of requiring general anesthesia for removal. Button battery foreign bodies carry the worst prognosis, with tympanic membrane perforation in up to 46% of cases, potential for facial nerve damage, and rare reports of labyrinthine fistula. Most canal skin lacerations and tympanic membrane perforations heal spontaneously within 4-8 weeks. Long-term sequelae are rare in uncomplicated cases. Parental education about small object safety and supervision during play is key to prevention in children. | T16.9XXA |
| 11 | 10 | Herpes Zoster Oticus (Ramsay Hunt Syndrome) | External Ear Disorders | Herpes zoster oticus, also known as Ramsay Hunt syndrome type II, results from reactivation of latent varicella-zoster virus (VZV) in the geniculate ganglion of the facial nerve (CN VII), producing a characteristic triad of ipsilateral facial nerve palsy, vesicular eruption of the ear (auricle, EAC, and/or tympanic membrane), and otic pain. VZV establishes lifelong latency in sensory ganglia following primary varicella (chickenpox) infection, persisting in a dormant state within neuronal cell bodies. Reactivation occurs when cell-mediated immunity declines, as with aging, immunosuppression, stress, or intercurrent illness, allowing the virus to replicate and travel along sensory nerve fibers to the skin. The geniculate ganglion is a sensory ganglion that receives afferent fibers from the auricle (via the nervus intermedius), the anterior two-thirds of the tongue (chorda tympani), and the palate, explaining the varied sensory distribution of the eruption. Because the facial motor nerve traverses the geniculate ganglion region, viral-induced inflammation and edema within the narrow fallopian canal compress the motor fibers, producing facial palsy. Involvement of the vestibulocochlear nerve (CN VIII), which lies in close proximity to CN VII within the internal auditory canal and cerebellopontine angle, occurs in 50-80% of cases, causing sensorineural hearing loss and vestibular dysfunction. Spread to adjacent cranial nerves (CN V, IX, X) may produce additional neurologic deficits in 10-30% of patients (polyneuritis cranialis). | Uncommon condition with an estimated incidence of 5-10 per 100,000 population per year. Ramsay Hunt syndrome accounts for approximately 7-12% of all unilateral facial nerve palsies, making it the second most common cause after Bell's palsy. The incidence increases significantly with age, rising from 2-3 per 100,000 in individuals under 60 to 15-20 per 100,000 in those over 75 years. Immunocompromised patients have a 5-10 fold increased risk of VZV reactivation. HIV-positive patients have a herpes zoster incidence 15-25 times higher than the general population. The introduction of the varicella vaccine may alter future epidemiology by reducing the latent reservoir, though this may be partially offset by reduced natural boosting of immunity. Males and females are affected equally. | Can occur at any age but is most common in adults over 60 years, with incidence increasing with each decade of life. The mean age at diagnosis is approximately 50-60 years. Pediatric cases are rare and occur almost exclusively in immunocompromised children. In immunocompetent individuals, the peak age range is 60-80 years, reflecting the natural decline in cellular immunity with aging. Adults under 50 who develop Ramsay Hunt syndrome should be evaluated for underlying immunodeficiency (HIV, lymphoproliferative disorders, iatrogenic immunosuppression). The availability of the herpes zoster vaccine (Shingrix) since 2017 has begun to reduce incidence in vaccinated populations over age 50. | Severe, deep, burning or lancinating otalgia often precedes the vesicular eruption by 24-72 hours (prodromal phase) and is the earliest symptom. The vesicular eruption appears as grouped vesicles on an erythematous base, typically involving the concha, antihelix, ear canal, and occasionally the tympanic membrane, as well as the ipsilateral hard palate and anterior two-thirds of the tongue (via chorda tympani distribution). Acute peripheral facial nerve palsy (ipsilateral lower motor neuron pattern affecting the entire hemiface) develops within 1-7 days of the eruption in 60-90% of patients, and is typically more severe than Bell's palsy. Sensorineural hearing loss occurs in 50-80% of patients, ranging from mild to profound, and may be sudden in onset. Vestibular symptoms including vertigo, nausea, nystagmus, and gait unsteadiness are present in 40-60% of cases. Dysgeusia (altered taste) on the anterior two-thirds of the tongue occurs in 30-50% due to chorda tympani involvement. Postherpetic neuralgia (persistent neuropathic pain after eruption resolution) develops in 20-40% of patients and can be debilitating. | Geniculate ganglion (CN VII); facial nerve (motor and sensory divisions); vestibulocochlear nerve (CN VIII); auricle and external auditory canal (sensory dermatome); anterior tongue and palate (chorda tympani); adjacent cranial nerves V, IX, X (in polyneuritis cranialis) | Clinical diagnosis based on the classic triad of ipsilateral facial palsy, herpetiform vesicular eruption of the ear, and otalgia. Zoster sine herpete (VZV reactivation without visible vesicles) may occur in 10-20% of cases, making diagnosis challenging; in these patients, PCR testing of saliva or tear fluid for VZV DNA or serologic testing for VZV-specific IgM and a 4-fold rise in IgG titers can confirm the diagnosis. Tzanck smear of vesicle fluid showing multinucleated giant cells provides rapid but non-specific confirmation. PCR of vesicle fluid or crusted lesion material for VZV DNA is the most sensitive and specific diagnostic test. Complete neurologic examination documents the degree of facial nerve function (House-Brackmann grading scale I-VI) and identifies involvement of additional cranial nerves. Audiometry (pure tone and speech audiometry) quantifies sensorineural hearing loss. Electroneuronography (ENoG) performed 3-14 days after onset predicts facial nerve recovery; degeneration exceeding 90% suggests poor prognosis. MRI with gadolinium enhancement of the temporal bone and internal auditory canal shows enhancement of the facial nerve (geniculate ganglion, labyrinthine, and tympanic segments) and may demonstrate CN VIII enhancement. Vestibular testing (videonystagmography, vestibular evoked myogenic potentials) documents vestibular involvement. | Antiviral therapy should be initiated as early as possible (ideally within 72 hours of rash onset): valacyclovir 1000 mg orally three times daily for 7 days (preferred due to superior bioavailability) or acyclovir 800 mg orally five times daily for 7-10 days. For immunocompromised patients or severe disease, IV acyclovir 10 mg/kg every 8 hours for 7-14 days is recommended. Systemic corticosteroids are used concurrently to reduce neural inflammation and edema: prednisone 1 mg/kg/day (maximum 60-80 mg) for 5 days, then tapered over 10-15 days. The combination of antivirals and corticosteroids has been shown to improve facial nerve recovery rates compared to either agent alone. Eye care is critical for patients with facial palsy: artificial tears (preservative-free) every 1-2 hours while awake, lubricating ophthalmic ointment at bedtime, and moisture chamber taping at night to prevent exposure keratopathy. Pain management includes gabapentin 300-1200 mg three times daily or pregabalin 75-150 mg twice daily for neuropathic pain, supplemented by NSAIDs or opioids for acute pain. For postherpetic neuralgia, tricyclic antidepressants (amitriptyline 25-75 mg at bedtime), capsaicin 8% patch, or lidocaine 5% patches are effective. Facial nerve decompression surgery via middle cranial fossa approach is controversial and generally reserved for cases with >90% degeneration on ENoG within 14 days and no voluntary electromyographic activity. | Facial nerve recovery in Ramsay Hunt syndrome is significantly worse than in Bell's palsy, with complete recovery occurring in only 50-70% of patients (compared to 85-95% for Bell's palsy). Patients with incomplete palsy (House-Brackmann grade II-III) have the best prognosis, with complete recovery in 70-90%. Complete palsy (House-Brackmann grade VI) recovers fully in only 30-50% of cases. Early antiviral plus corticosteroid therapy within 72 hours improves the recovery rate by 20-30%. Sensorineural hearing loss recovers partially or fully in approximately 50-60% of patients. Vestibular compensation typically occurs over 3-6 months regardless of peripheral vestibular damage. Postherpetic neuralgia persists beyond 3 months in 20-40% of patients, with risk increasing with age and severity of initial eruption. Synkinesis (aberrant facial nerve regeneration causing involuntary associated movements) develops in 15-25% of patients with severe initial palsy. Rarely, encephalitis, myelitis, or cerebral vasculitis (VZV vasculopathy) can complicate the course. | B02.21 |
| 12 | 11 | Keratosis Obturans | External Ear Disorders | Keratosis obturans is a condition characterized by the abnormal accumulation of desquamated keratinized epithelial debris within the external auditory canal, forming a dense plug of laminated keratin that fills and progressively expands the bony canal. The fundamental pathology involves a failure of the normal lateral epithelial migration of the EAC skin, which ordinarily moves desquamated keratin outward from the tympanic membrane at a rate of approximately 0.05 mm per day. In keratosis obturans, the epithelial migration pattern is disrupted, leading to concentric accumulation of keratinous material rather than orderly outward extrusion. The accumulated keratin mass exerts pressure on the bony canal walls, causing pressure necrosis and gradual widening (ballooning) of the bony EAC, a hallmark distinguishing feature. There is a strong association with bronchiectasis (reported in 39-77% of cases) and chronic sinusitis, suggesting a possible link to abnormal mucociliary clearance mechanisms or an underlying disorder of epithelial keratinization. The condition is bilateral in approximately 50% of cases, further suggesting a systemic rather than local etiology. Keratosis obturans must be distinguished from external auditory canal cholesteatoma, which involves focal bone erosion rather than diffuse canal widening. | Rare condition with an estimated prevalence of 0.01-0.1% of otologic clinic populations. A large otologic referral center may see 4-6 new cases per year. The association with bronchiectasis raises the prevalence in pulmonary specialty populations, where 5-10% of bronchiectasis patients may have concurrent keratosis obturans. Bilateral involvement in approximately 50% of cases means prevalence per patient is lower than per ear. There is no clear racial or ethnic predilection. The condition is significantly less common than cerumen impaction but more common than external auditory canal cholesteatoma. | Typically presents in younger patients, with the majority of cases diagnosed between ages 15 and 40 years, and mean age at diagnosis of approximately 30-35 years. This younger age distribution contrasts with external auditory canal cholesteatoma, which predominantly affects elderly patients. Pediatric cases have been reported but are uncommon. The association with bronchiectasis means that patients may already be under pulmonary care when the ear condition is identified. | Acute, severe otalgia is the most common presenting symptom, often described as deep and throbbing, resulting from the pressure of the expanding keratin plug on the sensitive periosteum of the bony canal. Sudden-onset conductive hearing loss is frequently reported, often bilateral, with air-bone gaps of 20-40 dB at presentation. The pain-hearing loss combination in a young patient is a classic presentation that should raise suspicion for keratosis obturans. On otoscopic examination, a dense, white-to-yellow, laminated keratin plug fills the EAC, often completely obscuring the tympanic membrane. After removal of the plug, the canal appears widened and ballooned with smooth, intact but erythematous canal skin. Associated symptoms of chronic sinusitis or productive cough may be present in patients with concurrent bronchiectasis. | External auditory canal (skin and bony walls); tympanic membrane (may be attenuated or thickened but is typically intact); bilateral involvement in 50% of cases | Otoscopic examination under microscopy reveals a dense plug of laminated desquamated keratin filling the EAC, distinguishable from cerumen by its firm, whitish, layered appearance. CT of the temporal bones demonstrates a soft tissue density mass filling a characteristically widened (ballooned) bony EAC without focal bone erosion or destruction, which is the key radiographic distinguishing feature from EAC cholesteatoma. Audiometry typically shows a conductive hearing loss of 20-40 dB that improves significantly after keratin plug removal. After debridement, the canal skin is inspected for integrity; in keratosis obturans the skin is inflamed but intact, unlike cholesteatoma where a focal defect is present. Histopathologic examination of the removed material shows layers of keratinized squamous epithelium without cholesterol crystals or chronic inflammatory infiltrate. Pulmonary function testing and chest CT should be considered given the association with bronchiectasis. Nasal endoscopy may reveal concurrent chronic sinusitis. | Removal of the keratin plug under microscopic guidance is the primary treatment, often requiring general anesthesia due to the severe pain associated with debridement and the adherence of the plug to inflamed canal skin. Topical steroid drops such as fluocinolone acetonide 0.01% oil-based drops 3-5 drops twice daily or betamethasone 0.1% drops are applied after debridement to reduce granulation tissue and promote normal epithelial migration. Regular follow-up with aural toilet every 3-6 months is essential to prevent reaccumulation, as the underlying epithelial migration disorder persists. Topical 5-fluorouracil cream 5% applied to the canal skin has been used in refractory cases to modulate keratinization, though evidence is limited. Antibiotic-steroid drops such as ciprofloxacin 0.3%/dexamethasone 0.1% 4 drops twice daily for 7-10 days are used if secondary infection is present. Surgical canalplasty is rarely required but may be considered for severely widened canals with chronic symptoms refractory to conservative management. Treatment of associated bronchiectasis and sinusitis should be coordinated with pulmonology and rhinology. | Chronic, relapsing condition requiring long-term follow-up and periodic debridement; cure is uncommon due to the persistent underlying epithelial migration defect. With regular surveillance and debridement every 3-6 months, symptoms can be well controlled in 80-90% of patients. Hearing normalizes after complete keratin plug removal in the majority of cases. Complications of untreated keratosis obturans include progressive canal widening with potential erosion into the mastoid or middle ear, secondary bacterial or fungal infection, and rarely, temporal bone osteomyelitis. Tympanic membrane perforation may occur if the expanding keratin mass applies sustained pressure. The associated bronchiectasis and sinusitis follow their own independent clinical courses. Recurrence rate without regular follow-up is nearly 100% within 6-12 months. | H60.40 |
| 13 | 12 | Malignant Otitis Externa | External Ear Disorders | Malignant (necrotizing) otitis externa is an aggressive, life-threatening infection of the external auditory canal that extends to the temporal bone and skull base, most commonly caused by Pseudomonas aeruginosa (>95% of cases). The infection originates at the junction of the cartilaginous and bony portions of the EAC, specifically at the fissures of Santorini, which are natural defects in the anterior-inferior cartilaginous canal floor that allow direct spread to the retromandibular soft tissues and skull base. Impaired neutrophil function and microangiopathy in diabetic patients create a permissive environment for Pseudomonas biofilm formation and tissue invasion. The organism produces exotoxin A, elastase, and alkaline protease that cause progressive necrotizing vasculitis and osteomyelitis of the temporal bone. Extension occurs along the skull base, potentially involving the temporomandibular joint, mastoid, petrous apex, clivus, and contralateral temporal bone. Cranial nerve involvement results from spread along neural foramina, with the facial nerve (CN VII) at the stylomastoid foramen being most commonly affected (occurring in 24-43% of cases), followed by CN IX, X, XI at the jugular foramen and CN XII at the hypoglossal canal. In rare cases, Aspergillus species or methicillin-resistant Staphylococcus aureus (MRSA) may be causative, particularly in severely immunosuppressed individuals. | Rare condition with an estimated incidence of 1-5 per 100,000 per year in the general population, but significantly higher in high-risk groups. Approximately 90-100% of patients have diabetes mellitus, with the remainder being immunocompromised from HIV/AIDS, chemotherapy, or organ transplantation. Diabetic patients have a 20-fold increased risk compared to the general population. The condition accounts for fewer than 1% of all otitis externa cases but carries a mortality rate of 10-20% in contemporary series (historically up to 50% before the advent of fluoroquinolone antibiotics). Males are affected approximately 1.7 times more frequently than females. Incidence has been rising due to the growing prevalence of diabetes and immunosuppressive therapies. | Predominantly affects elderly patients over 60 years of age, with mean age at presentation of 65-70 years. More than 75% of cases occur in patients over 55 years. Younger patients may be affected when severe immunocompromise is present, such as uncontrolled HIV with CD4 counts below 200 cells/microL, or patients on intensive immunosuppressive regimens following solid organ transplantation. Pediatric cases are exceedingly rare, reported primarily in neonates and children with congenital immunodeficiency syndromes. There is no significant racial or ethnic predisposition independent of diabetes prevalence. | Severe, unrelenting deep otalgia that is characteristically worse at night and disproportionate to otoscopic findings is the hallmark symptom, often persisting despite standard otitis externa treatment. Purulent, foul-smelling otorrhea is present in 80-90% of cases and may be blood-tinged. Granulation tissue at the bone-cartilage junction of the EAC floor (the pathognomonic finding) is visible on otoscopy in 70-80% of patients. Cranial neuropathies manifest as facial nerve palsy (ipsilateral peripheral facial weakness), hoarseness (CN X), dysphagia (CN IX, X), shoulder weakness (CN XI), or tongue deviation (CN XII). Trismus indicates involvement of the temporomandibular joint or pterygoid musculature. Temporal headache and referred pain to the ipsilateral temporoparietal region are common, and systemic symptoms including low-grade fever, malaise, and weight loss may be present. | External auditory canal; temporal bone; skull base (clivus, petrous apex, occipital bone); cranial nerves VII, IX, X, XI, XII; temporomandibular joint; parotid gland; nasopharynx in advanced cases | High-resolution CT of the temporal bone with contrast demonstrates soft tissue obliteration of the EAC, bony erosion of the tympanic bone and mastoid, and extent of skull base involvement. Technetium-99m bone scintigraphy is highly sensitive (100%) for detecting osteomyelitis and is used for initial diagnosis, though it lacks specificity for monitoring treatment response. Gallium-67 citrate scanning is the preferred modality for monitoring treatment response, as uptake normalizes with successful therapy. MRI with gadolinium enhancement is superior for evaluating soft tissue extension, intracranial involvement, dural enhancement, and cranial nerve involvement. Biopsy of granulation tissue is mandatory to exclude squamous cell carcinoma, which can mimic malignant otitis externa clinically and radiographically. Culture and sensitivity of deep tissue specimens guide antibiotic selection. ESR and CRP are typically markedly elevated (ESR >70 mm/hr, CRP >50 mg/L) and serve as useful monitoring parameters during treatment. | Prolonged systemic anti-pseudomonal antibiotic therapy is the mainstay of treatment. Empiric therapy typically begins with intravenous ciprofloxacin 400 mg every 8 hours or piperacillin-tazobactam 4.5 g every 6 hours, adjusted based on culture sensitivities. Oral ciprofloxacin 750 mg twice daily for a minimum of 6-8 weeks (and often 3-6 months) may follow initial IV therapy, guided by serial gallium scanning and inflammatory markers. For ciprofloxacin-resistant Pseudomonas, intravenous ceftazidime 2 g every 8 hours or meropenem 1 g every 8 hours combined with an aminoglycoside such as tobramycin 5-7 mg/kg/day is recommended. Fungal malignant otitis externa (Aspergillus) requires prolonged voriconazole 200 mg twice daily or amphotericin B 0.5-1 mg/kg/day IV. Local aural toilet and topical antibiotic/antifungal drops are adjunctive. Hyperbaric oxygen therapy at 2.0-2.5 ATA for 90 minutes daily for 20-30 sessions has shown benefit in refractory cases by enhancing neutrophil bactericidal activity and promoting angiogenesis. Surgical debridement is reserved for sequestrated bone and abscess drainage, with extensive resection generally avoided. | Mortality rate has decreased from 50% in the pre-fluoroquinolone era to 10-20% in current practice with aggressive antibiotic therapy. Facial nerve palsy at presentation is associated with a 50-60% recovery rate with treatment. Involvement of multiple cranial nerves or contralateral extension portends a significantly worse prognosis, with mortality approaching 30-40%. Recurrence rate is 15-20% and typically occurs within the first year of completing therapy, necessitating long-term surveillance. Complete resolution of gallium scan activity correlates with treatment success in 90% of cases. Diabetic patients with well-controlled HbA1c (<7%) have significantly better outcomes. Patients surviving the acute infection may have permanent cranial nerve deficits in 30-40% of cases. | H60.20 |
| 14 | 13 | Osteoma of Ear Canal | External Ear Disorders | Osteoma of the external auditory canal is a benign, pedunculated (stalked) bony neoplasm arising from the bony EAC, distinct from exostoses in its etiology and morphology. Unlike exostoses, osteomas are true neoplasms rather than reactive bone growths, and they are not associated with cold-water exposure. They arise from the tympanosquamous or tympanomastoid suture lines of the bony canal, typically as solitary, unilateral lesions with a well-defined bony stalk. Histologically, osteomas consist of mature lamellar bone with fibrofatty marrow spaces and Haversian canal systems, distinguishing them from the dense compact bone of exostoses. The etiology is unknown, though they may arise from embryonic periosteal rests or represent hamartomatous growth at the suture lines of the temporal bone. Growth is typically slow and progressive, with the tumor enlarging over years to decades. Some osteomas contain a mixture of compact and cancellous bone (ivory and spongy types respectively), with ivory osteomas being more common in the ear canal. Rare familial cases have been reported, and an association with Gardner syndrome (familial adenomatous polyposis with extracolonic manifestations) should be considered when multiple osteomas are present. | Rare benign tumor, with osteomas of the ear canal accounting for fewer than 1% of all benign ear tumors. Estimated prevalence is 0.01-0.05% of the general population based on temporal bone studies. Incidental osteomas are found in approximately 0.1-0.3% of temporal bone CT scans performed for other indications. Unlike exostoses, there is no strong gender predilection, though a slight male predominance (1.3:1) has been reported in some series. The condition is sporadic with no clear geographic, ethnic, or occupational associations. Osteomas represent approximately 10-15% of all bony growths encountered in the EAC, with exostoses being far more common. | Can occur at any age but is most commonly diagnosed in the third to fifth decades of life (ages 20-50 years). The slow growth rate means that many osteomas are present for years before becoming symptomatic. Pediatric cases are rare but have been reported, particularly in the context of Gardner syndrome where multiple osteomas may present in childhood or adolescence. There is no clear age at onset since growth may begin years before clinical detection. | Many small osteomas are asymptomatic and discovered incidentally on otoscopic examination or radiographic imaging. When symptomatic, progressive conductive hearing loss is the most common complaint, occurring when the osteoma grows large enough to occlude more than 50% of the canal lumen. Recurrent cerumen impaction lateral to the osteoma is a frequent presenting problem, as the mass disrupts normal epithelial migration and cerumen clearance. Recurrent otitis externa may develop secondary to water and debris trapping behind the obstructing mass. Aural fullness and a foreign body sensation in the affected ear are commonly described. Otalgia is generally mild or absent unless complicated by secondary infection. | External auditory canal (bony portion, arising from suture lines); tympanic membrane (secondary involvement from retained debris) | Otoscopic examination reveals a smooth, hard, skin-covered, pedunculated mass in the bony EAC, usually arising from the posterior-superior canal wall at the tympanosquamous suture line. High-resolution CT of the temporal bones is the definitive imaging study, demonstrating a well-circumscribed, dense bony mass with a distinct stalk (peduncle), often with internal marrow spaces visible in spongy-type osteomas. CT accurately delineates the attachment point, relationship to the tympanic membrane and ossicular chain, and degree of canal obstruction. Audiometry is indicated to document hearing status and characterize any conductive hearing loss. Biopsy is generally not required when imaging is characteristic, but histologic examination after excision confirms the diagnosis and excludes osteosarcoma (exceedingly rare in this location). MRI is rarely needed but may be useful to evaluate associated soft tissue abnormalities. When multiple osteomas are identified, genetic evaluation for Gardner syndrome including colonoscopy screening is recommended. | Observation with serial examination is appropriate for small, asymptomatic osteomas that do not obstruct the canal. Surgical excision via transcanal approach is indicated for symptomatic lesions causing hearing loss, recurrent infections, or inability to examine the tympanic membrane. The surgical technique involves elevating the canal skin flap over the osteoma, identifying the stalk, and removing the tumor using a combination of curettes, osteotomes, and otologic drill with diamond burrs under microscopic visualization. The pedunculated nature of osteomas generally allows complete excision with less drilling than required for exostosis removal. Postoperative care includes antibiotic-impregnated packing (ciprofloxacin otic drops on Gelfoam) for 1-2 weeks, topical antibiotic-steroid drops such as ciprofloxacin 0.3%/dexamethasone 0.1% for 2-3 weeks, and water precautions for 4-6 weeks until complete re-epithelialization. Large osteomas abutting the tympanic membrane may require a postauricular approach for improved visualization and safety. | Excellent prognosis following complete surgical excision, with recurrence rates of less than 1-2% due to the pedunculated growth pattern allowing complete removal at the stalk. Hearing recovery to preoperative baseline or better is achieved in more than 95% of surgically treated patients. Surgical complications are uncommon and include tympanic membrane perforation (1-2%), canal stenosis (<3%), sensorineural hearing loss (<1%), and facial nerve injury (extremely rare). Asymptomatic osteomas that are observed may remain stable for many years, though slow growth is expected. There is no known risk of malignant transformation. Patients with Gardner syndrome require ongoing surveillance for intestinal polyposis and other extracolonic manifestations. | D16.4 |
| 15 | 14 | Otitis Externa | External Ear Disorders | Diffuse inflammation of the external auditory canal (EAC) skin and subdermis, most commonly caused by bacterial infection with Pseudomonas aeruginosa (accounting for 50-70% of cases) and Staphylococcus aureus (15-30% of cases). The pathogenesis involves disruption of the protective cerumen-lipid barrier lining the EAC, which normally maintains an acidic pH of 4.0-5.0 that inhibits bacterial and fungal growth. Predisposing factors include excessive moisture exposure (swimming, humid climates), mechanical trauma from cotton swabs or hearing aids, dermatologic conditions such as eczema or psoriasis, and immunocompromised states. Water exposure macerates the EAC skin epithelium, raising the pH toward alkalinity and creating a favorable environment for pathogenic colonization. The warm, dark, and moist environment of the ear canal serves as an ideal incubator once the natural defenses are compromised. In tropical and subtropical regions, polymicrobial infections including gram-negative rods are more prevalent. Chronic otitis externa lasting more than 3 months may develop in approximately 3-5% of cases, often associated with allergic or dermatologic etiologies rather than purely infectious causes. | Very common condition affecting approximately 1 in 123 people (0.81%) annually in the United States, translating to roughly 2.4 million healthcare visits per year. Lifetime prevalence is estimated at 10% of the general population. Incidence peaks during summer months with a 2-3 fold increase compared to winter, and is notably higher in tropical climates. Swimmers have a 5-fold increased risk compared to non-swimmers, earning the condition the colloquial name 'swimmer's ear.' The condition accounts for approximately 25-50% of all otologic visits in primary care settings. Annual direct healthcare costs in the US exceed $500 million. | Can occur at any age but peak incidence is in the 7-12 year age group and again in adults aged 45-65 years. Children are particularly susceptible due to narrower ear canals and frequent water exposure during recreational swimming. Neonates and infants under 2 years are relatively less affected due to limited water exposure. In elderly populations, hearing aid use and decreased cerumen production increase susceptibility. | Otalgia (ear pain) is the predominant symptom, often severe and disproportionate to clinical findings, exacerbated by tragal pressure, auricular traction, or jaw movement during mastication. Pruritus frequently precedes pain and may be the initial presenting complaint. Otorrhea is present in 50-60% of cases, typically scant, clear-to-purulent discharge that may become mucopurulent in advanced stages. Conductive hearing loss occurs when edema or debris obstructs the EAC lumen, reported in 20-30% of cases. Aural fullness and a sensation of canal occlusion are common accompanying symptoms. In severe cases, periauricular cellulitis with erythema, edema extending to the pinna and surrounding soft tissue, and regional lymphadenopathy (preauricular and postauricular nodes) may develop. | External auditory canal; tympanic membrane (may have secondary involvement); auricle and periauricular tissue in severe cases | Clinical diagnosis based on otoscopic examination revealing erythema, edema, and narrowing of the EAC with possible purulent debris. Tragal tenderness and pain on auricular traction are pathognomonic examination findings distinguishing otitis externa from otitis media. Pneumatic otoscopy should be performed when the tympanic membrane is visible to exclude concurrent middle ear pathology. Culture and sensitivity testing of canal discharge is recommended in refractory cases, recurrent infections, or immunocompromised patients. Microscopic examination under the operating microscope may be necessary when canal edema precludes adequate visualization. CT imaging of the temporal bone is reserved for suspected complications including mastoiditis or malignant otitis externa. Audiometry should be performed if hearing loss is reported to establish baseline and quantify any conductive component. | Topical therapy is the cornerstone of treatment, with fluoroquinolone drops such as ciprofloxacin 0.3%/dexamethasone 0.1% (Ciprodex) 4 drops twice daily for 7 days or ofloxacin 0.3% (Floxin Otic) 10 drops once daily for 7 days being first-line agents. Acetic acid 2% (VoSol) 5 drops three times daily serves as an acidifying agent for mild cases. Aural toilet with gentle suctioning or dry mopping under microscopic guidance is essential to remove debris and allow topical medication penetration. A wick (Pope ear wick or Merocel) should be inserted when canal edema prevents drop penetration, with drops applied to the wick and wick removed after 48-72 hours. Oral analgesics including ibuprofen 400-600 mg every 6-8 hours or acetaminophen 500-1000 mg every 6 hours for pain management. Systemic antibiotics such as ciprofloxacin 500 mg twice daily for 7-10 days are reserved for cases with periauricular cellulitis, fever, or immunocompromised patients. Water precautions with avoidance of swimming and use of protective ear plugs during bathing are essential during treatment. | Excellent prognosis with appropriate topical therapy; 65-90% of patients achieve complete resolution within 7-10 days. Recurrence rate is approximately 12-25% within the first year, often related to ongoing predisposing factors such as continued water exposure or hearing aid use. Chronic otitis externa develops in 3-5% of patients and may require prolonged or repeated courses of treatment. Complications including periauricular cellulitis occur in fewer than 5% of cases. Progression to malignant otitis externa is rare but carries significant morbidity and occurs primarily in diabetic and immunocompromised patients. With proper prophylactic measures including acidifying drops after water exposure, recurrence can be substantially reduced. | H60.90 |
| 16 | 15 | Otomycosis | External Ear Disorders | Otomycosis is a superficial fungal infection of the external auditory canal, most commonly caused by Aspergillus species (Aspergillus niger in 60-70% of cases, Aspergillus fumigatus in 10-15%) and Candida species (Candida albicans in 15-25%). The pathogenesis involves disruption of the normal EAC microenvironment that allows fungal overgrowth: elevated canal humidity (>80%), alkaline pH shift (above the normal acidic pH of 4-5), depletion of normal bacterial flora (often by topical antibiotic therapy), and loss of the protective cerumen lipid barrier. Prior bacterial otitis externa treated with prolonged topical antibiotic drops is the most common predisposing factor, as antibiotics eliminate competing bacterial flora and create an ecological niche for fungal colonization. Other risk factors include tropical/humid climates (prevalence is 2-4 times higher in tropical regions), immunosuppression (diabetes mellitus, HIV/AIDS, systemic corticosteroid use), swimming, hearing aid use, and habitual ear cleaning that removes protective cerumen. Aspergillus species form characteristic filamentous mycelia (hyphae) with sporulating heads (conidiophores) visible on microscopy and otoscopy, while Candida species produce budding yeast forms with pseudohyphae. Fungal biofilm formation on the canal skin and tympanic membrane surface contributes to treatment resistance and recurrence. | Common condition representing 9-30% of all otitis externa cases worldwide, with higher prevalence in tropical and subtropical climates (up to 30%) compared to temperate regions (9-15%). Global incidence is estimated at 15-20 million cases annually. In tropical countries (Southeast Asia, Africa, Middle East), otomycosis accounts for 20-25% of all outpatient otologic consultations. The condition affects approximately 0.5-1% of the general population annually in temperate climates and 2-4% in tropical climates. HIV-positive patients have a 3-5 fold increased risk, and diabetic patients have a 2-3 fold increased risk. Males and females are equally affected. Recurrence rate is notably high at 15-30%, contributing to repeated clinic visits. | Can occur at any age but is most commonly diagnosed in adults aged 20-50 years. Tropical climate exposure and occupational factors (outdoor workers, swimmers) contribute to higher incidence in working-age adults. Pediatric otomycosis is less common than bacterial otitis externa but occurs in children who swim frequently or have been treated with prolonged topical antibiotics. Elderly patients with diabetes, hearing aids, and impaired immunity are at increased risk. In immunocompromised patients, otomycosis may present at any age and can be the initial manifestation of underlying immunodeficiency. | Intense pruritus (itching) of the ear is the most prominent symptom, often described as deep and maddening, and is more pronounced than in bacterial otitis externa. Aural fullness and a sensation of blockage are reported by 80-90% of patients as fungal hyphae and debris accumulate in the canal. Otalgia (pain) is variable, typically less severe than in bacterial otitis externa unless secondary bacterial infection is present. Otorrhea is present in 50-70% of cases, typically thick, cheesy, or cotton-like in appearance, which may be white (Candida), black (Aspergillus niger), or yellow-green (Aspergillus flavus). Otoscopic examination reveals characteristic fungal debris: Aspergillus niger produces pathognomonic black-dotted cotton-ball-like masses (conidiophores), while Candida produces creamy white, paste-like deposits. Hearing loss occurs in 30-40% of patients due to canal obstruction by fungal debris, and tinnitus may accompany the hearing loss. | External auditory canal (skin and cerumen layer); tympanic membrane (may show fungal plaques in 15-20% of cases); middle ear (rare, in cases of tympanic membrane perforation) | Otoscopic and microscopic examination is the primary diagnostic method, revealing characteristic fungal hyphae and spore masses. Aspergillus niger produces black or dark brown spore heads ('wet newspaper' or 'blotting paper' appearance) against a white-gray mycelial background. Candida appears as creamy white plaques or paste-like material. KOH (potassium hydroxide) wet mount preparation of canal debris demonstrates septate branching hyphae (Aspergillus) or budding yeast with pseudohyphae (Candida) under light microscopy, providing rapid confirmation. Fungal culture on Sabouraud dextrose agar is the gold standard for species identification, with results typically available in 5-14 days. Gram stain and bacterial culture should also be performed to identify concurrent bacterial co-infection. Audiometry is indicated if hearing loss is reported. In refractory or invasive cases (immunocompromised patients), CT temporal bone imaging and biopsy should be considered to exclude invasive fungal infection or malignancy. | Thorough aural toilet with microscopic-guided suctioning to mechanically remove all visible fungal debris is the essential first step and significantly improves outcomes. Topical antifungal agents are first-line therapy: clotrimazole 1% solution 3-4 drops three times daily for 3-4 weeks is the most widely used and effective agent, achieving cure rates of 82-95%. Miconazole 2% cream applied to the EAC daily for 3-4 weeks is an alternative for Candida-predominant infection. Acetic acid 2% (VoSol) or aluminum acetate solution (Burow's solution) 5 drops three times daily creates an acidic environment inhospitable to fungal growth and may be used as monotherapy for mild cases or as adjunctive therapy. Tolnaftate 1% or nystatin 100,000 units/mL drops are alternatives for Candida species. For Aspergillus-predominant infection resistant to topical azoles, amphotericin B deoxycholate 3% solution ear drops applied twice daily for 2-3 weeks may be used. For refractory or recurrent cases, oral antifungal therapy with fluconazole 200 mg daily for 2-4 weeks (Candida) or itraconazole 200 mg twice daily for 1-2 weeks then 200 mg daily for 2-4 weeks (Aspergillus) may be necessary. Importantly, topical antibiotic drops should be discontinued as they perpetuate the fungal infection. Keeping the ear dry with water precautions is essential during treatment. | Good prognosis with appropriate antifungal therapy and aural toilet, with initial cure rates of 82-95% for topical clotrimazole. Recurrence is the major challenge, occurring in 15-30% of patients within 3-6 months of completing treatment, often due to persistent predisposing factors such as humidity, hearing aid use, or immunosuppression. Multiple courses of treatment may be required, and some patients require long-term prophylactic acidifying drops (acetic acid 2% twice weekly) to prevent recurrence. Complications are rare and include tympanic membrane perforation (1-2%), secondary bacterial infection (10-15%), and canal stenosis from chronic inflammation (<1%). Invasive fungal otitis externa (analogous to malignant otitis externa) is extremely rare and occurs almost exclusively in severely immunocompromised patients. In immunocompetent patients, the condition does not cause permanent hearing loss, and hearing normalizes after clearance of fungal debris. | B36.9 |
| 17 | 16 | Perichondritis of the Pinna | External Ear Disorders | Perichondritis is an infection of the perichondrium, the connective tissue layer that envelops the auricular cartilage and provides its sole vascular supply. Pseudomonas aeruginosa is the most common causative organism, accounting for 45-65% of culture-positive cases, followed by Staphylococcus aureus (20-30%) and polymicrobial infections (10-15%). The most frequent predisposing factor in contemporary practice is high ear piercing through the auricular cartilage (particularly helix and tragus piercings), accounting for 30-50% of cases; standard earlobe piercings rarely cause perichondritis because the lobule contains no cartilage. Other etiologies include auricular trauma, burns (thermal, chemical, or frostbite), surgical wounds (otoplasty, mastoidectomy), insect bites, and extension from otitis externa. The infection begins in the perichondrium and can rapidly progress to involve the underlying cartilage (chondritis), leading to avascular necrosis since cartilage has no intrinsic blood supply and depends on perichondrial diffusion. Devitalized cartilage serves as a foreign body that perpetuates infection and impedes healing. Abscess formation between the perichondrium and cartilage further compromises cartilage viability and can result in severe permanent deformity if not promptly treated. | Relatively common in clinical practice, with perichondritis representing 3-8% of all ear infections presenting to emergency departments. The incidence has increased significantly over the past two decades due to the rising popularity of high cartilage ear piercings, with some studies showing a 3-fold increase in cases. Piercing-related perichondritis affects approximately 3-5% of individuals with high ear piercings (helix, industrial, tragus), compared to less than 0.5% for earlobe piercings. Post-surgical perichondritis occurs in 1-3% of otoplasty and 0.5-1% of mastoidectomy cases. Burn-related auricular perichondritis occurs in up to 25% of patients with burns involving the ear. No significant gender difference exists, though females may present more frequently due to higher rates of ear piercing. | Can occur at any age, but the incidence is highest in adolescents and young adults aged 16-30 years, reflecting the peak age group for ear piercings. Post-traumatic and burn-related perichondritis can occur at any age. Surgical-related perichondritis tends to occur in older children (post-otoplasty) or adults (post-mastoidectomy). There is no inherent age-related susceptibility to the infection itself, with the distribution driven primarily by exposure to predisposing factors. | Progressive auricular pain, erythema, and swelling involving the cartilaginous portions of the pinna are the cardinal presenting features, characteristically sparing the lobule (which lacks cartilage). The ear becomes increasingly tender, warm, and edematous, often over 24-72 hours, with the affected area developing a dusky red or violaceous hue. Loss of normal auricular contour and landmarks occurs as edema distorts the pinna, giving the ear a rounded, featureless appearance. In the abscess formation stage, focal fluctuance may be palpable, and the ear becomes exquisitely tender with possible purulent drainage from the piercing site or traumatic wound. Systemic symptoms including fever, malaise, and regional lymphadenopathy (preauricular and postauricular) develop in moderate to severe cases. If untreated, cartilage necrosis leads to progressive deformity similar to cauliflower ear, with the potential for partial or complete loss of the auricular framework. | Auricle (pinna): perichondrium and auricular cartilage; surrounding soft tissue; preauricular and postauricular lymph nodes | Clinical diagnosis based on the triad of pain, erythema, and swelling of the cartilaginous auricle with lobule sparing. Aspiration of any fluctuant collection with aerobic and anaerobic cultures and Gram stain is essential for guiding targeted antibiotic therapy. Blood cultures should be obtained if systemic sepsis is suspected. Laboratory studies including complete blood count, ESR, and CRP help assess severity and monitor treatment response. Ultrasound (high-frequency linear probe) can identify subperichondrial abscess formation and guide aspiration. CT of the temporal bone with contrast is indicated in severe cases to exclude extension of infection to the temporal bone, mastoid, or intracranial structures. Differential diagnosis includes relapsing polychondritis (bilateral, painless in early stages, positive anti-type II collagen antibodies), auricular cellulitis (involves lobule and does not respect cartilage distribution), and erysipelas (sharply demarcated, involves lobule). | Systemic antibiotics with anti-pseudomonal activity are first-line therapy, typically initiated empirically with ciprofloxacin 750 mg orally twice daily or levofloxacin 750 mg orally once daily for mild-to-moderate cases. Severe cases require intravenous therapy with piperacillin-tazobactam 4.5 g every 6 hours, ceftazidime 2 g every 8 hours, or ciprofloxacin 400 mg IV every 8 hours, often combined with vancomycin 15-20 mg/kg IV every 8-12 hours for MRSA coverage pending cultures. Minimum antibiotic duration is 10-14 days, extended to 4-6 weeks if chondritis or abscess has developed. Abscess drainage is performed via an anterior incision along the antihelix, with evacuation of purulent material and necrotic cartilage, followed by placement of a Penrose drain or through-and-through bolster sutures. Topical antibiotics such as gentamicin 0.3% or ciprofloxacin 0.3% drops applied directly to drainage sites provide adjunctive local coverage. Aggressive pain management with NSAIDs (ibuprofen 600 mg every 6-8 hours) and opioids if needed. If a piercing is the source, the jewelry must be removed immediately. Warm compresses applied for 15-20 minutes four times daily promote blood flow and antibiotic delivery. | Prognosis is favorable when treatment is initiated early (within 48 hours of symptom onset), with complete resolution without deformity in 85-90% of promptly treated cases. Delayed treatment beyond 72 hours or inadequate antibiotic coverage significantly increases the risk of cartilage necrosis and permanent auricular deformity, occurring in 20-40% of late-presenting cases. Abscess formation requiring surgical drainage is associated with a 30-50% risk of some degree of permanent deformity. Recurrence rate is approximately 5-10% and is higher in immunocompromised patients and those with retained foreign bodies (piercings). Cosmetic reconstruction (otoplasty) may be offered for established deformity, though results are variable. Rarely, severe perichondritis can progress to necrotizing soft tissue infection, temporal bone osteomyelitis, or sepsis, particularly in immunocompromised individuals. | H61.009 |
| 18 | 17 | Relapsing Polychondritis (Auricular) | External Ear Disorders | Relapsing polychondritis (RP) is a rare, systemic autoimmune disorder characterized by recurrent episodes of inflammation and progressive destruction of cartilaginous structures throughout the body, with the auricle being the most commonly affected site. The pathogenesis involves autoimmune targeting of type II, IX, and XI collagen (the primary structural proteins of cartilage), with both humoral (anti-collagen antibodies) and cell-mediated immune mechanisms contributing to cartilage destruction. Circulating antibodies to type II collagen are detected in 30-70% of patients during active disease flares. Histopathologically, active lesions show loss of basophilic staining of the cartilage matrix (representing proteoglycan depletion), infiltration by lymphocytes, plasma cells, and neutrophils at the chondro-perichondrial junction, and progressive replacement of cartilage by fibrous tissue. CD4+ T lymphocytes predominate in the inflammatory infiltrate, suggesting a Th1-mediated immune response. The disease may occur in isolation or in association with other autoimmune conditions (30% of cases), including systemic vasculitis, rheumatoid arthritis, systemic lupus erythematosus, and myelodysplastic syndrome (particularly in older males). Auricular chondritis is the presenting manifestation in approximately 40% of cases and occurs at some point during the disease course in 85-95% of patients. The lobule is characteristically spared because it contains no cartilage. | Rare disease with an estimated incidence of 3.5-4.5 per million per year and a prevalence of approximately 4.5 per million population. The condition is likely underdiagnosed due to its variable presentation and lack of specific diagnostic biomarkers. Approximately 500-600 new cases are diagnosed annually in the United States. No consistent racial or ethnic predilection has been established, though most reported cases are in Caucasian populations, possibly reflecting referral bias. Males and females are affected equally or with a slight female predominance (1:1 to 1.2:1 female-to-male ratio). Associated myelodysplastic syndrome occurs in approximately 10-25% of patients over 60 years of age. | Peak age of onset is in the fourth to fifth decades of life (ages 40-60 years), with a mean age at diagnosis of approximately 47 years. The disease can occur at any age, with rare pediatric cases reported as young as 2 years. Juvenile-onset relapsing polychondritis (before age 18) accounts for fewer than 5% of all cases and may have a different clinical profile with more frequent airway involvement. When associated with myelodysplastic syndrome, the onset tends to be later, typically after age 60. The diagnosis is often delayed by 2-5 years from symptom onset due to the episodic nature and variable presentation. | Auricular chondritis presents with sudden onset of pain, erythema, and swelling of one or both ears, characteristically involving the cartilaginous portions while sparing the non-cartilaginous lobule, which is the clinical hallmark. The affected auricle is warm, tender, and may appear violaceous or dusky red. Episodes typically last 5-10 days and resolve spontaneously, but recurrent attacks lead to cumulative cartilage destruction and progressive deformity. Over time, the auricle becomes soft, floppy, and misshapen, eventually developing the classic 'floppy ear' or 'droopy ear' deformity due to loss of structural cartilage support. Bilateral involvement is present in 85% of patients at some point during the disease course. Associated features in other organ systems may include nasal chondritis (saddle nose deformity), laryngotracheal chondritis (stridor, dyspnea), arthritis, ocular inflammation (episcleritis, scleritis, uveitis), audiovestibular dysfunction (sensorineural hearing loss in 30-50%), and cardiovascular involvement (aortitis, valvular regurgitation). | Auricle (pinna cartilage); nasal cartilage; laryngeal and tracheal cartilage; costal cartilage; joints; eyes (sclera, uvea); inner ear (cochlea, vestibular apparatus); cardiovascular system (aorta, heart valves) | Diagnosis is clinical, based on the McAdam diagnostic criteria (1976) requiring 3 or more of: bilateral auricular chondritis, non-erosive seronegative inflammatory polyarthritis, nasal chondritis, ocular inflammation, respiratory tract chondritis, and audiovestibular damage. Modified Damiani-Levine criteria require only one McAdam criterion plus histologic confirmation, or two McAdam criteria with response to corticosteroids. Biopsy of affected auricular cartilage shows characteristic loss of basophilic matrix staining, chondrocyte depletion, and perichondrial inflammatory infiltrate with lymphocytes and plasma cells. Laboratory studies demonstrate elevated ESR (>30 mm/hr in 80% of active cases), elevated CRP, normocytic anemia, and anti-type II collagen antibodies (present in 30-70% during flares but not specific). Audiometry reveals sensorineural hearing loss in 30-50% of patients. CT and MRI of the airway evaluate laryngotracheal involvement. Echocardiography screens for valvular disease and aortitis. Pulmonary function tests may show fixed upper airway obstruction. A comprehensive autoimmune panel and peripheral blood smear are recommended to evaluate for associated conditions. | Acute flares are treated with systemic corticosteroids: prednisone 0.5-1 mg/kg/day orally for 2-4 weeks, then tapered over 4-8 weeks guided by clinical response and inflammatory markers. NSAIDs such as indomethacin 25-50 mg three times daily may suffice for mild auricular-only disease. Dapsone 50-100 mg daily has been used as a steroid-sparing agent for predominantly auricular disease with variable success. Colchicine 0.6 mg twice daily may be beneficial for mild-moderate disease. For moderate-to-severe or relapsing disease, steroid-sparing immunosuppressive agents include methotrexate 15-25 mg weekly, azathioprine 2-2.5 mg/kg/day, mycophenolate mofetil 1-1.5 g twice daily, or cyclophosphamide 2 mg/kg/day for life-threatening involvement (airway, vascular). Biologic agents including infliximab 5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks, adalimumab 40 mg subcutaneously every 2 weeks, or tocilizumab 8 mg/kg IV every 4 weeks have shown efficacy in refractory cases. Airway involvement may require emergent tracheostomy or tracheal stenting. Auricular reconstruction with prosthetics or autologous rib cartilage grafting may be considered for established deformity once disease is quiescent. | The clinical course is highly variable, ranging from mild auricular-only disease with infrequent flares to severe multisystem involvement with significant morbidity and mortality. The 5-year survival rate is approximately 74-95% and 10-year survival is 55-80%, depending on the extent of organ involvement. Mortality is most commonly attributed to airway compromise (laryngotracheal collapse), cardiovascular disease (aortitis, valvulopathy), and infection related to immunosuppressive therapy. Auricular deformity is permanent once cartilage is destroyed but is primarily a cosmetic concern. Patients with predominantly auricular disease have the best prognosis. Development of myelodysplastic syndrome in older patients confers an independent poor prognosis. Sensorineural hearing loss, once established, is generally irreversible. Early initiation of immunosuppressive therapy can significantly reduce the frequency and severity of flares and slow disease progression. | M94.1 |
| 19 | ▸ Middle Ear Disorders | |||||||||||
| 20 | 18 | Adhesive Otitis Media | Middle Ear Disorders | Adhesive otitis media represents the end stage of chronic middle ear inflammation in which dense fibrous adhesions obliterate the middle ear space, binding the tympanic membrane to the ossicular chain, promontory, and other medial wall structures. The condition develops through a sequence beginning with chronic Eustachian tube dysfunction, progressing through middle ear atelectasis (Sade Grade IV), and culminating in fibrous tissue proliferation that permanently fuses the retracted tympanic membrane to the medial wall of the middle ear. The pathological process involves chronic mucosal inflammation stimulating fibroblast activity and excessive collagen deposition, leading to organization of middle ear effusion into fibrous adhesions. The inflammatory milieu includes elevated levels of interleukin-1, interleukin-6, tumor necrosis factor-alpha, and transforming growth factor-beta, which drive the fibrotic process. Loss of the middle ear air cushion eliminates the space necessary for ossicular vibration and sound transmission. The ossicular chain becomes encased in fibrous tissue and may undergo necrosis, particularly the long process of the incus. Tympanosclerotic plaques may coexist within the adhesions, further rigidifying the system. The condition is considered irreversible once established, as the fibrous tissue is resistant to medical dissolution and tends to reform after surgical lysis. The mastoid air cell system is typically poorly developed or completely opacified in adhesive otitis media, reflecting the longstanding Eustachian tube dysfunction. | Adhesive otitis media is a relatively uncommon end-stage condition, representing approximately 2-5% of chronic otitis media cases in otological surgical series. The prevalence in the general population is estimated at 0.1-0.5%. Higher prevalence is observed in populations with endemic chronic otitis media, including Aboriginal Australian communities (2-5%), Inuit populations, and Native American communities. The condition is more common in patients with cleft palate, Down syndrome, and Turner syndrome. Bilateral involvement occurs in approximately 30-40% of cases. | Adhesive otitis media develops over many years of chronic middle ear disease, typically presenting in late adolescence or adulthood (ages 15-40 years) following a childhood history of recurrent otitis media or chronic middle ear effusion. The condition may develop earlier in high-risk populations (cleft palate patients, syndromic patients) and in settings with inadequate treatment of chronic ear disease. The onset is insidious, with gradual progression from retraction to adhesion over 5-15 years. | Significant conductive hearing loss is the predominant symptom, typically 30-55 dB, reflecting both the loss of the tympanic membrane sound-collecting function and ossicular chain immobility. The hearing loss is stable and non-fluctuating, unlike the variable loss of middle ear effusion. The ear is characteristically dry, distinguishing it from active chronic otitis media with drainage. Tinnitus occurs in approximately 40-50% of patients. Ear fullness may be minimal as the condition represents a chronic, stable state. Otoscopic examination reveals a featureless tympanic membrane plastered against the promontory with obscured landmarks and absent light reflex. Occasional episodes of acute otitis media may still occur through the Eustachian tube, despite the obliterated middle ear space. | Tympanic membrane; middle ear space (obliterated); ossicular chain (encased in fibrous tissue); promontory; mastoid air cells (underdeveloped or opacified); Eustachian tube | Otoscopy and otomicroscopy demonstrate a retracted, immobile tympanic membrane adherent to the medial wall of the middle ear, with absent or severely reduced mobility on pneumatic otoscopy. Tympanometry shows a flat (Type B) tracing with normal ear canal volume, which is indistinguishable from middle ear effusion. Pure tone audiometry reveals moderate to severe conductive hearing loss (30-55 dB air-bone gap) with preserved bone conduction thresholds. HRCT temporal bones demonstrates opacified middle ear space with loss of normal air density, poor mastoid pneumatization, possible ossicular erosion, and tympanic membrane-promontory contact. MRI may be indicated to differentiate adhesive otitis from cholesteatoma, using diffusion-weighted imaging (DWI) which shows no restricted diffusion in adhesive otitis unlike cholesteatoma. Surgical exploration provides definitive assessment of the middle ear contents and ossicular status. | Management of adhesive otitis media is challenging with no consistently effective treatment. Hearing aids (conventional air conduction or bone-anchored hearing aids) are the mainstay of rehabilitation and provide reliable hearing improvement. Surgical intervention with tympanoplasty and adhesiolysis has been attempted but carries high recurrence rates (50-70%) as fibrous adhesions tend to reform. Cartilage tympanoplasty using thick cartilage grafts (full-thickness tragal or conchal cartilage) provides the best resistance to re-retraction and re-adhesion. Silicone sheeting (Silastic) placed in the middle ear as a spacer to prevent re-adhesion during healing has been used with variable success. Ossiculoplasty with titanium PORP or TORP is performed when ossicular chain reconstruction is feasible, though results in adhesive otitis are poorer than in non-adhesive chronic ear disease. Mastoid obliteration with staged procedures may be required for extensive disease. Bone-anchored hearing aids (Baha, Osia) or active middle ear implants (Vibrant Soundbridge) provide reliable hearing rehabilitation when tympanoplasty fails or is not appropriate. Prevention through early treatment of Eustachian tube dysfunction and chronic ear effusion is the most effective strategy. | Prognosis for hearing recovery through surgery is generally poor, with successful hearing improvement in only 30-50% of surgical cases and high recurrence rates of adhesion. Cartilage grafts show better long-term stability with graft survival exceeding 85%, but hearing outcomes remain variable. Revision surgery success rates are progressively lower with each attempt. Hearing aids provide consistent and reliable hearing rehabilitation. The condition is not life-threatening but significantly impacts quality of life through hearing disability and communication difficulties. There is a small risk of cholesteatoma development within residual retraction pockets. Long-term audiological monitoring every 1-2 years is recommended. Bone-anchored hearing aids demonstrate excellent user satisfaction rates exceeding 80% in this population. | H74.19 |
| 21 | 19 | Cholesteatoma (Acquired) | Middle Ear Disorders | Acquired cholesteatoma is a destructive and expanding growth of keratinizing stratified squamous epithelium within the middle ear cleft, representing an abnormal accumulation of epithelial tissue that does not belong in this location. The retraction pocket theory is the most widely accepted pathogenetic mechanism: chronic Eustachian tube dysfunction creates negative middle ear pressure, causing retraction of the pars flaccida (most commonly) or posterior-superior pars tensa, forming a pocket that traps desquamated keratin debris which cannot be naturally extruded. The epithelial migration theory proposes that squamous epithelium from the ear canal migrates through a marginal tympanic membrane perforation into the middle ear. Squamous metaplasia of the middle ear mucosa, transforming respiratory epithelium to keratinizing squamous epithelium under chronic inflammatory stimulus, represents a third mechanism. Once established, the cholesteatoma expands through enzymatic bone destruction mediated by collagenases (MMP-2, MMP-9), acid phosphatases, osteoclast-activating cytokines (RANKL, TNF-alpha, IL-1), and pressure necrosis from the expanding mass. The perimatrix (inflammatory tissue surrounding the cholesteatoma matrix) is the biologically active layer responsible for bone erosion. Cholesteatoma can erode the ossicular chain, tegmen tympani (risking intracranial complications), facial nerve canal, and labyrinth (causing sensorineural hearing loss and vertigo). Secondary infection of the cholesteatoma produces foul-smelling purulent otorrhea characteristic of the disease. | The incidence of acquired cholesteatoma is approximately 3-12 per 100,000 population annually in developed countries. Prevalence is estimated at 10-15 per 100,000 adults. The incidence is approximately 2-3 times higher in the pediatric population compared to adults. Male-to-female ratio is approximately 1.4-1.5:1. Bilateral cholesteatoma occurs in approximately 5-10% of cases. Higher prevalence in socioeconomically disadvantaged populations with limited access to healthcare for treatment of chronic otitis media. Incidence has declined in developed nations over recent decades with improved management of otitis media and Eustachian tube dysfunction. | Acquired cholesteatoma can develop at any age but is most commonly diagnosed between ages 10-40 years, with peak incidence in adolescents and young adults. Pediatric cholesteatoma (under 16 years) represents approximately 25-30% of cases and tends to be more aggressive with higher recurrence rates. The earliest acquired cholesteatomas may develop from retraction pockets beginning in childhood (ages 5-10 years). Adult cholesteatoma typically presents in the third to fifth decades. Elderly patients may present with long-standing, extensively destructive disease that has been asymptomatic for decades. | Chronic foul-smelling purulent otorrhea is the most characteristic symptom, present in approximately 70-80% of cases, often resistant to topical antibiotic therapy. Progressive conductive hearing loss occurs in 80-90% of patients, typically 20-50 dB, due to ossicular erosion and mass effect. The hearing may be paradoxically preserved if the cholesteatoma creates a bridge between the tympanic membrane and stapes, transmitting sound directly (columellar effect). Otalgia suggests complicated disease with possible extracranial abscess or dural involvement. Vertigo indicates labyrinthine erosion (lateral semicircular canal most commonly) and occurs in approximately 10-15% of cases. Facial nerve weakness occurs in 1-3% of cases from facial nerve canal erosion. Headache, fever, and neck stiffness are alarming symptoms suggesting intracranial complications (meningitis, brain abscess, sigmoid sinus thrombosis). | Middle ear cavity; mastoid; ossicular chain (incus long process eroded most commonly); tegmen tympani; lateral semicircular canal; facial nerve canal; sigmoid sinus plate; petrous apex in extensive disease | Otoscopy and otomicroscopy reveal characteristic pearly-white or grayish-white epithelial debris, typically in the pars flaccida retraction (attic cholesteatoma) or posterior-superior pars tensa region, often with surrounding granulation tissue and purulent discharge. HRCT temporal bones with thin sections demonstrates a non-dependent soft tissue mass in the middle ear or mastoid with associated bone erosion of the scutum (outer attic wall), ossicular chain, tegmen, labyrinth, or facial nerve canal. MRI with diffusion-weighted imaging (DWI) is the most sensitive non-invasive method for confirming cholesteatoma, showing restricted diffusion (high signal on DWI, low signal on ADC maps) with sensitivity and specificity exceeding 90%. Non-echo planar imaging DWI (non-EPI DWI, such as HASTE or PROPELLER) provides superior resolution for small cholesteatomas and is the preferred sequence. Pure tone audiometry documents conductive, mixed, or sensorineural hearing loss. CT or MR angiography may be indicated when vascular complications (sigmoid sinus thrombosis) are suspected. Surgical exploration remains essential for definitive assessment and treatment. | Surgery is the only definitive treatment for cholesteatoma, as it will not resolve spontaneously and has potential for serious complications if left untreated. Canal wall up (CWU) mastoidectomy with tympanoplasty preserves the posterior canal wall, maintains normal ear canal anatomy, and is preferred when disease extent allows complete removal through this approach; however, recidivism rates are 15-30%, necessitating planned second-look surgery at 9-12 months. Canal wall down (CWD) mastoidectomy or modified radical mastoidectomy removes the posterior canal wall to provide wider surgical access and lower recidivism rates (5-10%) but creates a mastoid cavity requiring lifelong maintenance. Endoscopic ear surgery (transcanal endoscopic approach) is increasingly used for limited cholesteatoma, offering improved visualization of hidden recesses (anterior epitympanum, sinus tympani) with reduced morbidity. Ossiculoplasty is performed simultaneously or as a staged procedure to reconstruct the eroded ossicular chain. Topical antibiotic drops (ciprofloxacin 0.3% or ofloxacin 0.3% otic solution, 5 drops twice daily) are used pre- and postoperatively to control infection. Aural toilet (regular microsuction cleaning) is essential for cavity care following CWD mastoidectomy. Intracranial complications require urgent surgical intervention with mastoidectomy, abscess drainage, and intravenous antibiotics (ceftriaxone 2 g IV every 12 hours plus metronidazole 500 mg IV every 8 hours). | With appropriate surgical management, cholesteatoma can be effectively controlled in 85-95% of cases, though it is generally considered a chronic condition requiring long-term follow-up. Recidivism (residual or recurrent disease) occurs in 15-30% of CWU procedures and 5-10% of CWD procedures. Pediatric cholesteatoma has higher recidivism rates (25-40%) due to more aggressive biological behavior. Non-EPI DWI MRI has significantly reduced the need for second-look surgery by detecting residual cholesteatoma as small as 2-3 mm. Hearing outcomes depend on the extent of ossicular destruction: ossiculoplasty achieves serviceable hearing (air-bone gap <20 dB) in 50-70% of cases. Untreated cholesteatoma carries risk of life-threatening intracranial complications including meningitis (most common), epidural abscess, brain abscess (temporal lobe, cerebellum), and lateral sinus thrombosis, with a historical mortality rate of 10-20% for intracranial complications. Modern neurosurgical and antibiotic management has reduced this mortality to 2-5%. Lifelong follow-up with annual otoscopy and periodic DWI MRI is recommended. | H71.90 |
| 22 | 20 | Cholesterol Granuloma of Middle Ear | Middle Ear Disorders | Cholesterol granuloma of the middle ear and mastoid is a foreign body giant cell reaction to cholesterol crystals deposited within the middle ear mucosa and mastoid air cell system. The pathogenesis is explained by the obstructive-vacuum theory: Eustachian tube dysfunction and mucosal obstruction of the aditus ad antrum or mastoid air cell tracts create isolated air cell compartments where gas is absorbed, generating negative pressure that ruptures mucosal blood vessels. The extravasated blood breaks down, releasing cholesterol from erythrocyte membranes and hemosiderin from hemoglobin degradation. These cholesterol crystals act as foreign bodies, inciting a chronic granulomatous inflammatory response characterized by multinucleated foreign body giant cells, hemosiderin-laden macrophages, fibrous tissue proliferation, and neovascularization. The granulomatous tissue is expansile, capable of eroding surrounding bone including the ossicular chain, tegmen tympani, and labyrinthine bone. The exposed hemorrhage theory offers an alternative explanation: direct hemorrhage into a well-pneumatized mastoid system produces the same foreign body reaction without requiring negative pressure. Cholesterol granuloma must be distinguished from cholesteatoma, which is an entirely different pathological entity consisting of keratinizing squamous epithelium. The petrous apex is the most common site for large cholesterol granulomas, but middle ear and mastoid involvement is more frequently encountered clinically. | The exact prevalence of middle ear cholesterol granuloma is not well established in population studies. It is identified in approximately 2-5% of chronic otitis media surgical specimens. Cholesterol granuloma is found in approximately 30-40% of temporal bones with chronic otitis media at autopsy. Petrous apex cholesterol granuloma is the most common lesion of the petrous apex but remains uncommon overall, with an estimated incidence of less than 1 per 100,000 population. Middle ear cholesterol granuloma is more common than petrous apex involvement. The condition has no significant gender predilection and occurs across all ethnic groups. | Middle ear cholesterol granuloma typically presents in adults aged 20-50 years with history of chronic Eustachian tube dysfunction or chronic otitis media. Petrous apex cholesterol granuloma may present at any age from childhood to elderly. The condition develops over months to years following initial hemorrhage and the inflammatory cascade. No specific age predilection exists beyond the association with chronic ear disease, which is more prevalent in younger adult populations. | Progressive conductive hearing loss is the most common presenting symptom when the middle ear is involved, due to mass effect on the ossicular chain and tympanic membrane. The characteristic finding on otoscopy is a blue or dark blue discoloration of the tympanic membrane (blue eardrum), resulting from the cholesterol-laden, hemosiderin-stained granulation tissue visible behind the drum. Ear fullness and pressure sensation are frequently reported. Chronic serous otorrhea may occur if there is concurrent tympanic membrane perforation. When cholesterol granuloma involves the petrous apex, symptoms include unilateral sensorineural hearing loss, tinnitus, facial nerve paresis (cranial nerve VII involvement), diplopia (abducens nerve compression), and headache. Vestibular symptoms may occur with labyrinthine erosion. | Middle ear cavity; mastoid air cells; ossicular chain; tympanic membrane; tegmen tympani; petrous apex in extensive disease; facial nerve canal; labyrinth in erosive disease | Otoscopy reveals a characteristic blue or dark blue tympanic membrane when fluid-filled middle ear is present, though this finding is not specific and must be differentiated from hemotympanum and glomus tumor. HRCT temporal bones demonstrates opacification of the middle ear and mastoid with possible bony expansion and erosion without the scalloped bone destruction pattern of cholesteatoma. MRI is the most valuable imaging modality: cholesterol granuloma shows characteristic high signal on both T1-weighted and T2-weighted sequences due to cholesterol crystals, methemoglobin, and protein-rich fluid content, distinguishing it from cholesteatoma (low T1, high T2) and mucocele (low T1, high T2). Diffusion-weighted MRI (DWI) shows no restricted diffusion, unlike cholesteatoma which demonstrates restricted diffusion on DWI. Histopathological examination of surgically removed tissue confirms the diagnosis with characteristic cholesterol clefts surrounded by foreign body giant cells, hemosiderin deposits, and fibrous tissue. Pure tone audiometry quantifies conductive or mixed hearing loss. | Middle ear cholesterol granuloma is managed surgically with tympanomastoidectomy to remove the granulation tissue, establish drainage, and restore middle ear aeration. Canal wall up (intact canal wall) or canal wall down (modified radical) mastoidectomy is performed depending on the extent of disease and status of the posterior canal wall. Concurrent ossiculoplasty with PORP or TORP addresses ossicular chain pathology. Tympanoplasty with cartilage graft reinforcement provides durable tympanic membrane reconstruction. For petrous apex cholesterol granuloma, drainage procedures include infralabyrinthine, infracochlear, or transmastoid approaches to create a permanent drainage pathway to the mastoid or nasopharynx. Middle fossa or translabyrinthine approaches may be needed for larger petrous apex lesions. Endoscopic transnasal approaches to the petrous apex are increasingly utilized. Conservative observation with serial imaging is appropriate for incidentally discovered, asymptomatic small lesions. Ventilation tube insertion addresses middle ear effusion in mild cases. | Surgical outcomes for middle ear cholesterol granuloma are generally favorable, with resolution of the granulomatous process in 80-90% of cases following adequate surgery and re-aeration. Hearing improvement depends on the degree of ossicular chain damage and success of reconstruction. Recurrence rates are approximately 10-20% if the underlying Eustachian tube dysfunction persists and middle ear aeration is not maintained. Petrous apex cholesterol granuloma has a higher recurrence rate of 10-30% following drainage procedures, requiring revision in some cases. Long-term stent or drainage tube placement in petrous apex cases reduces recurrence. Serial MRI monitoring is recommended following treatment of petrous apex lesions. The condition itself is benign and does not undergo malignant transformation. Prognosis for cranial nerve deficits (facial nerve, abducens) depends on the duration and degree of compression prior to surgical decompression. | H74.8X9 |
| 23 | 21 | Congenital Cholesteatoma | Middle Ear Disorders | Congenital cholesteatoma is a keratinizing squamous epithelial cyst arising behind an intact tympanic membrane in the absence of any history of ear infection, tympanic membrane perforation, or ear surgery. The pathogenesis is explained by the epidermoid formation theory proposed by Michaels, which describes a transient collection of squamous epithelial cells (epidermoid formation) normally present in the anterosuperior quadrant of the developing middle ear between the 10th and 33rd weeks of gestation that typically involutes before birth. Failure of this physiological involution results in persistence and gradual expansion of the epithelial remnant as a cholesteatoma. The consistent anterosuperior location of many congenital cholesteatomas supports this developmental theory. Alternative theories include implantation of squamous cells during embryonic development and squamous metaplasia of middle ear epithelium. Congenital cholesteatoma demonstrates the same biological behavior as acquired cholesteatoma, with progressive expansion, keratin accumulation, and bone erosion through enzymatic and pressure-mediated mechanisms. However, congenital cholesteatoma is typically a closed cyst with an intact perimatrix and tends to present earlier with less extensive bone destruction. The Potsic staging system classifies congenital cholesteatoma: Stage I (single quadrant involvement), Stage II (multiple quadrants without ossicular or mastoid involvement), Stage III (ossicular erosion without mastoid extension), and Stage IV (mastoid extension). Open congenital cholesteatoma that has eroded through the tympanic membrane may be indistinguishable from acquired cholesteatoma. | Congenital cholesteatoma accounts for approximately 2-5% of all cholesteatomas in most series, though recent literature suggests the incidence may be increasing due to improved detection. The estimated incidence is approximately 0.12 per 100,000 live births. In pediatric otology practices, congenital cholesteatoma represents approximately 15-25% of cholesteatoma cases in children. Male predominance with male-to-female ratio of approximately 3:1 to 4:1. Bilateral congenital cholesteatoma is rare, reported in less than 2% of cases. The condition is more commonly diagnosed in Caucasian children. Mean age at diagnosis has decreased over recent decades due to increased awareness and improved otoscopic screening. | Most commonly diagnosed between ages 2-7 years, with a mean age at diagnosis of approximately 5 years. The cholesteatoma is present from birth but grows slowly, requiring years to reach a size detectable on otoscopy or to produce symptoms. Earlier diagnosis (under age 3) typically occurs when a white mass is incidentally noted behind the tympanic membrane during routine otoscopic examination or well-child visits. Later presentation (age 8-15 years) occurs when the cholesteatoma has grown large enough to cause hearing loss or has eroded into the mastoid. Adult diagnosis is uncommon and suggests extremely slow growth or missed earlier detection. | The most common presentation is an asymptomatic white mass visible behind an intact tympanic membrane, typically in the anterosuperior quadrant, discovered incidentally during routine otoscopic examination. Progressive conductive hearing loss of 15-40 dB develops as the cholesteatoma enlarges and contacts or erodes the ossicular chain. Parents may notice hearing difficulties or the child may fail a school hearing screening. Unlike acquired cholesteatoma, there is characteristically no history of ear drainage, ear infections, or ear surgery. The ear canal is clean and the tympanic membrane is intact and mobile except where directly overlying the mass. Late presentations with large cholesteatomas may show symptoms identical to acquired cholesteatoma including otorrhea (if the cholesteatoma erodes through the tympanic membrane), vertigo, and rarely facial nerve weakness. | Middle ear cavity (anterosuperior quadrant most commonly); ossicular chain; mastoid (in advanced stages); rarely labyrinth and facial nerve canal | Otoscopy reveals a characteristic white, spherical, pearl-like mass behind an intact tympanic membrane, most commonly visible in the anterosuperior quadrant. The Levenson diagnostic criteria for congenital cholesteatoma require: (1) white mass behind an intact tympanic membrane, (2) normal pars tensa and pars flaccida, (3) no history of ear discharge or perforation, (4) no history of ear surgery. HRCT temporal bones demonstrates a non-dependent soft tissue mass in the middle ear, defines its relationship to the ossicular chain, and assesses for bone erosion and mastoid extension. MRI with diffusion-weighted imaging (DWI) confirms cholesteatoma by demonstrating restricted diffusion and is essential for preoperative staging and postoperative surveillance. Pure tone audiometry documents conductive hearing loss. Auditory brainstem response (ABR) may be needed for young children who cannot cooperate with behavioral audiometry. Staging according to the Potsic classification guides surgical planning and prognosis. | Surgical excision is the treatment for all congenital cholesteatomas regardless of stage, as the lesion will inevitably grow and cause progressive destruction. Transcanal endoscopic ear surgery (TEES) is increasingly the preferred approach for Stage I-II disease, offering magnified visualization, reduced morbidity, and avoidance of postauricular incision. Microscopic transcanal or postauricular approach with tympanomeatal flap elevation provides access for Stage I-III disease. Canal wall up (CWU) mastoidectomy with tympanoplasty is performed for Stage III-IV disease with mastoid extension, preserving the posterior canal wall. Canal wall down mastoidectomy is rarely necessary for congenital cholesteatoma. Ossiculoplasty is performed when ossicular chain erosion is identified, either primarily or as a staged procedure. For closed cyst-type congenital cholesteatoma, careful intact removal of the cyst is attempted to minimize residual disease. Planned second-look surgery at 6-12 months or surveillance non-EPI DWI MRI at 12 months is recommended to detect residual cholesteatoma. Ciprofloxacin 0.3% otic drops are used perioperatively if infection is present. | Surgical outcomes for congenital cholesteatoma are generally more favorable than for acquired cholesteatoma, particularly for early-stage disease. Stage I-II disease has residual cholesteatoma rates of only 5-10% following complete excision. Stage III-IV disease has residual rates of 20-35%, approaching those of acquired cholesteatoma. Hearing outcomes are excellent for early-stage disease with intact ossicular chain, with return to normal hearing in 80-90% of Stage I cases. Recidivism rates are lower than acquired cholesteatoma because the absence of Eustachian tube dysfunction and retraction pocket removes the mechanism for recurrent disease. Early detection and early-stage surgery significantly improve outcomes. Long-term follow-up with otoscopy and DWI MRI surveillance for a minimum of 5 years is recommended. The mean time to detection of residual disease is approximately 2-3 years. Overall disease-free survival at 5 years exceeds 85% for Stage I-II and approximately 65-75% for Stage III-IV. | H71.90 |
| 24 | 22 | Congenital Ossicular Fixation | Middle Ear Disorders | Congenital ossicular fixation results from developmental abnormalities during embryogenesis affecting the first and second branchial arch derivatives from which the ossicles form between the 4th and 30th weeks of gestation. The malleus and incus derive from Meckel's cartilage (first branchial arch), while the stapes superstructure originates from Reichert's cartilage (second branchial arch) and the footplate from the otic capsule. Fixation most commonly involves the malleus head to the epitympanic wall through bony bridging or the stapes footplate to the oval window margin. Unlike otosclerosis, congenital stapes fixation involves the entire footplate with a thickened, immobile footplate rather than focal otospongiotic foci. The condition may occur in isolation or as part of broader syndromes including branchio-oto-renal syndrome, Treacher Collins syndrome, Pierre Robin sequence, or chromosomal anomalies such as trisomy 18 and 21. Congenital fixation of the malleus head to the tegmen tympani or anterior epitympanic wall is the most common pattern of congenital ossicular fixation. The underlying genetic mechanisms involve disruption of homeobox genes (HOXA1, HOXA2) and signaling pathways (endothelin-1, FGF) critical for branchial arch patterning. Histologically, the fixation consists of mature lamellar bone bridging between the ossicle and surrounding temporal bone without the vascular, spongy bone characteristic of otosclerosis. | Congenital ossicular anomalies as a group account for approximately 0.5-1.5% of congenital hearing loss cases. Congenital stapes fixation represents the most common isolated congenital ossicular anomaly, with an estimated prevalence of 1 in 10,000-15,000 live births. Congenital malleus fixation accounts for approximately 15-20% of congenital ossicular anomalies. Male-to-female ratio is approximately equal. Bilateral involvement occurs in 30-40% of cases. The condition represents approximately 5-10% of all cases of unexplained conductive hearing loss in children and young adults. | Present from birth, though diagnosis is often delayed until ages 5-15 years when unilateral or bilateral conductive hearing loss is identified on school hearing screenings or when the child fails to develop age-appropriate speech and language milestones. Unilateral cases may not be detected until adulthood, sometimes not until the third or fourth decade. Earlier diagnosis is typical when the condition is bilateral or associated with syndromic features. Newborn hearing screening may detect the conductive loss if it exceeds 30-35 dB. | Conductive hearing loss is the cardinal symptom, typically stable and non-progressive, ranging from 25-55 dB depending on which ossicle is fixed and the degree of fixation. Patients may present with speech delay or academic difficulties in childhood if the loss is bilateral and undetected. The ear canal, tympanic membrane, and middle ear mucosa appear entirely normal on otoscopic examination, making clinical diagnosis challenging. Tinnitus is uncommon in congenital fixation, unlike acquired otosclerosis. There is no history of chronic ear infections, trauma, or ear surgery. Vertigo is absent unless there is an associated inner ear anomaly, which occurs in approximately 10-15% of cases. | Ossicular chain (malleus head, incus body, stapes footplate); epitympanic space; oval window; rarely inner ear structures in syndromic cases | Pure tone audiometry reveals conductive hearing loss with air-bone gap, stable over serial testing, which is a distinguishing feature from progressive otosclerosis. Tympanometry shows Type As (reduced compliance) or normal tympanogram; acoustic reflexes are absent. HRCT temporal bones with submillimeter sections is the key diagnostic study, demonstrating bony bridging between ossicles and surrounding bone, thickened or malformed stapes footplate, or fusion of the malleus head to the epitympanic wall. CT clearly differentiates congenital fixation (bony fusion, normal otic capsule) from otosclerosis (lucent focus at fissula ante fenestram). Three-dimensional CT reconstructions aid surgical planning by defining the exact anatomy of the fixation. Exploratory tympanotomy provides definitive diagnosis and allows simultaneous surgical correction. Auditory brainstem response confirms conductive hearing loss pattern in young children who cannot cooperate with behavioral audiometry. | Hearing aids are the first-line treatment, particularly for children during critical speech and language development years. Surgical correction depends on the type and location of fixation: for congenital stapes fixation, stapedotomy similar to the otosclerosis procedure can be performed with creation of a small fenestra and prosthesis placement. For malleus fixation, surgical options include malleus head removal with reconstruction or laser-assisted lysis of the bony bridge. Incus fixation may require incus removal and ossicular reconstruction with prosthesis. Bone-anchored hearing devices (Baha Connect, Baha Attract, Osia, Ponto) provide excellent non-surgical hearing rehabilitation, particularly for bilateral cases or when surgical anatomy is unfavorable. In children, surgery is typically deferred until age 6-8 years when the ear canal is large enough for adequate surgical access. Active middle ear implants such as the Vibrant Soundbridge offer an alternative for cases not suitable for conventional surgery or hearing aids. Genetic counseling is recommended for syndromic cases. | Hearing outcomes with stapes surgery for congenital fixation are somewhat less favorable than for otosclerosis, with air-bone gap closure to within 10 dB achieved in 60-75% of cases versus 90-95% for otosclerosis. The risk of sensorineural hearing loss from surgery is slightly higher (2-5%) due to frequent anatomic variations including aberrant facial nerve course (30% of congenital stapes cases). Hearing aids provide reliable hearing rehabilitation with no surgical risks. The hearing loss itself is stable and non-progressive in most cases. Inner ear anomalies, when present, may be associated with progressive sensorineural component. Long-term follow-up shows stable surgical results in 70-80% of successful cases at 10 years. Bone-anchored hearing aids demonstrate excellent long-term outcomes with user satisfaction rates exceeding 85%. | Q16.3 |
| 25 | 23 | Ear Barotrauma | Middle Ear Disorders | Ear barotrauma (middle ear barotrauma or aerotitis media) results from failure to equalize pressure between the middle ear cavity and the external environment during changes in ambient pressure, leading to mechanical stress on the tympanic membrane and middle ear structures. According to Boyle's law, gas volume is inversely proportional to pressure; during descent (increasing pressure), the middle ear gas volume contracts, creating relative negative pressure that requires active Eustachian tube opening to equilibrate. The Eustachian tube functions as a one-way valve that opens more readily during ascent (positive middle ear pressure) than descent (negative middle ear pressure), making squeeze injuries during descent more common. When the pressure differential across the tympanic membrane exceeds approximately 60-80 mmHg, Eustachian tube locking occurs as the compliant nasopharyngeal tubal orifice collapses under the negative pressure gradient, preventing equalization. Progressive negative middle ear pressure causes mucosal engorgement, transudate formation, hemorrhage, and ultimately tympanic membrane rupture at differentials exceeding 100-150 mmHg. The Teed classification grades middle ear barotrauma from Grade 0 (symptoms only) through Grade 5 (tympanic membrane perforation). Risk factors include pre-existing Eustachian tube dysfunction, upper respiratory infection, allergic rhinitis, nasal polyps, and sleep during airplane descent. Diving barotrauma follows identical pathophysiology but with more rapid and extreme pressure changes (every 10 meters of seawater adds 1 atmosphere of pressure). | Middle ear barotrauma is the most common diving-related medical condition, affecting approximately 30-40% of novice divers and 10-15% of experienced divers. In air travelers, mild barotrauma symptoms (ear pressure, discomfort) occur in an estimated 10-20% of passengers during descent. Clinically significant barotrauma requiring medical attention occurs in approximately 1-2% of air travelers. Tympanic membrane perforation from barotrauma occurs in approximately 1-5% of diving barotrauma cases and less than 0.01% of air travel. Military personnel in aviation and diving operations have higher rates due to more extreme pressure exposures. Hyperbaric oxygen therapy patients experience barotrauma in 2-10% of sessions. | Can occur at any age during pressure-change activities. Peak incidence in recreational divers aged 20-40 years. Air travel-related barotrauma can affect all ages but is more problematic in children aged 1-8 years due to immature Eustachian tube function and inability to perform equalization maneuvers effectively. Infants during air travel are particularly vulnerable. Military aviation-related barotrauma predominantly affects young adults aged 18-35 years. Hyperbaric medicine patients are often older adults aged 50-70 years with multiple comorbidities. | Acute onset of severe otalgia during descent (diving or flying) is the cardinal symptom, often described as sharp, deep ear pain that may radiate to the temporal region and jaw. Ear fullness and pressure sensation may persist for hours to days after the inciting event. Conductive hearing loss ranging from 10-35 dB develops with middle ear effusion or hemorrhage. Tinnitus occurs in approximately 50-60% of cases. Vertigo and nausea develop if the pressure differential is sufficient to cause inner ear barotrauma (perilymph fistula or inner ear hemorrhage), which represents a more serious complication. Bloody otorrhea indicates tympanic membrane rupture, which paradoxically relieves the pain as pressure equalizes. Caloric vertigo may occur if cold water enters the middle ear through a perforation during diving. | Tympanic membrane; middle ear cavity and mucosa; Eustachian tube; in severe cases: inner ear (round window membrane, oval window); ossicular chain | Clinical history is paramount, with clear temporal relationship between pressure change and symptom onset. Otoscopic examination reveals findings graded by the Teed classification: Grade 1 (tympanic membrane retraction and injection along malleus handle), Grade 2 (tympanic membrane injection with mild hemorrhage), Grade 3 (gross hemorrhage within the tympanic membrane), Grade 4 (hemotympanum with blood visible in the middle ear), Grade 5 (tympanic membrane perforation). Pure tone audiometry documents conductive hearing loss and identifies any sensorineural component suggesting inner ear involvement. Tympanometry demonstrates negative middle ear pressure (Type C) or effusion (Type B). In cases with vertigo or sensorineural hearing loss, urgent assessment for perilymph fistula is warranted with fistula test and possible surgical exploration. CT temporal bones is indicated for suspected ossicular injury or when inner ear barotrauma is clinically suspected. Electronystagmography evaluates vestibular function when vertigo is prominent. | Mild barotrauma (Teed Grade 1-2) is managed conservatively with oral decongestants (pseudoephedrine 60 mg every 6 hours for 5-7 days), topical nasal decongestant sprays (oxymetazoline 0.05%, 2 sprays each nostril twice daily for 3-5 days), and intranasal corticosteroids (fluticasone propionate 50 mcg, 2 sprays each nostril daily). Oral analgesics (ibuprofen 400-600 mg three times daily or acetaminophen 1000 mg every 6 hours) manage pain. Moderate barotrauma (Grade 3-4) with persistent effusion may require myringotomy for drainage if not resolving within 2-4 weeks. Oral antibiotics (amoxicillin 500 mg three times daily for 7 days) are prescribed if secondary infection develops. Autoinflation techniques (Valsalva maneuver, Frenzel maneuver, Toynbee maneuver) facilitate equalization. Prophylactic measures for future pressure exposure include pre-treatment with pseudoephedrine 60 mg 30-60 minutes before descent, nasal corticosteroid spray, and equalization technique training. Tympanic membrane perforation from barotrauma typically heals spontaneously with dry ear precautions. Suspected inner ear barotrauma (perilymph fistula) requires bed rest, head elevation, and avoidance of straining, with surgical exploration and repair if symptoms persist. | Excellent prognosis for Grade 1-3 barotrauma, with complete resolution of symptoms and hearing within 1-4 weeks in over 90% of cases. Grade 4 (hemotympanum) resolves within 4-8 weeks in most cases. Tympanic membrane perforations from barotrauma heal spontaneously in approximately 80-90% of cases. Inner ear barotrauma with perilymph fistula carries a more guarded prognosis, with permanent sensorineural hearing loss in 20-40% of cases despite treatment. Vestibular symptoms typically resolve over weeks to months with central compensation. Recurrence is common (30-50%) with continued pressure exposure unless underlying Eustachian tube dysfunction is addressed or proper equalization technique is mastered. Prophylactic tympanostomy tube placement may be considered for patients requiring hyperbaric oxygen therapy or frequent pressure exposure who have recurrent barotrauma. | T70.0XXA |
- Full dataset access
- Excel format
- Instant download